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During Impaired Cutaneous Wound Healing in a Murine Model of Diabetes 
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Wound healing is an extremely intricate and highly dynamic process. High 
throughput molecular screening technologies such as DNA microarrays hold 
great potential in enhancing our understanding of complex biological processes, 
and have been extensively utilized in wound healing research. However, 
analyzing time series gene expression data remains challenging in large part due 
to small sample size, irregularly spaced time points, missing values, noisy 
observations, and high-dimensionality of the data. Additionally, the temporal 
order and potential dependence of observations may introduce complex 
correlation structure in the data, which if ignored can lead to loss of information 
and reduced statistical power. Previous attempts at analyzing transcriptional 
response during cutaneous wound healing have been limited to conventional 
statistical methods that are either oblivious to temporal order and dependence of 
observations, or incapable of handling the irregularities commonly encountered 
in time course studies. As a result, there is a substantial need for a statistical 
framework that allows for irregularities in design while taking the temporal 
order and potential dependence of observations into account.  
 
Functional data analysis (FDA) provides a natural and fruitful way to fill this 
gap, and has recently emerged as a powerful and flexible approach to analyze 
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time series gene expression data. In FDA, discrete observations are viewed as 
noisy realizations of a smooth function over time. By treating the entire sequence 
of time series data as a single functional entity, FDA directly utilizes the 
temporal structure and potential dependence of measurements to borrow 
information across observations. While several FDA-based methods have been 
proposed to analyze time series gene expression data, none has been applied to 
transcriptional response during cutaneous wound healing. Moreover, the 
existing literature on application of FDA to time series gene expression data is 
heavily focused on identifying differentially expressed genes, leaving a holistic 
view of FDA-based analysis convoluted in the eye of practitioners. Therefore, the 
overarching objective of this dissertation was to devise and implement a 
comprehensive functional analysis of time series gene expression data, using a 
previously published microarray study of transcriptional response during 
impaired cutaneous wound healing in a murine model of diabetes. 
 
We pursued this objective via three specific aims. A fundamental goal of 
analyzing transcriptional response during wound healing is to identify genes 
that exhibit change of expression over time or have distinct temporal pattern 
between two or more study groups. In the first aim, we pursued this goal by 
combining the likelihood ratio procedure with smoothing spline representation 
of gene expression data to compare the expression profile of each gene over the 
course of healing in diabetic skin (db/db) versus controls (db/+). Furthermore, 
we demonstrated the unique utility of spline-based methods in pointwise 
comparison of gene expression profiles at time points beyond those dictated by 
study design. Interpreting the list of differentially expressed genes and extracting 
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actionable information from genome-wide dynamic regulation of gene 
expression are challenging, and have been the subject of active research over the 
past decade. Gene set analysis (GSA) is one approach to decipher the vast pool of 
information obtained from high throughput transcriptome data by utilizing the 
prior knowledge about the functional role and biological association of genes. 
Application of GSA procedures to time course studies, however, is not 
straightforward. In the second aim we showed how FDA can be utilized to 
extend existing GSA procedures originally developed for static studies with 
simple case-control designs, to time course studies with complex scenarios. 
Moreover, we applied a powerful and intuitive functional statistic to test 
differential expression of selected gene sets over time in db/db skin compared to 
db/+, while taking the potential heterogeneity of gene sets into account. Finally, 
it has become increasingly evident that cellular and molecular components of 
biological systems do not act in solitary. Instead, they interact as elements of 
highly interconnected networks. Characterizing the structure and dynamic of 
this web of interactions holds great potential in deciphering complex biological 
processes. In the third aim we took advantage of smooth curve representation of 
time course gene expression data, and used a functional measure of pairwise 
coexpression to construct gene coexpression networks for db/db and db/+ 
wounds. Consequently, we utilized the network architecture of gene 
coexpression in conjunction with GSA to speculate about the biological 
contribution of a candidate gene to cutaneous wound healing. 
 
Taken together, this work presents a comprehensive functional approach to 
transcriptional analysis of impaired diabetic wound healing. Building upon the 
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rich and flexible framework of FDA, it shows how FDA circumvents various 
challenges associated with analyzing time series data, and demonstrate its utility 
in different aspects of gene expression analysis, from differential expression, to 
gene set testing, to coexpression network analysis. Collectively, this work allows 
us to gain better understanding of cellular and molecular mediators of impaired 
healing, and sheds light on novel genes and biological processes implicated in 
impaired diabetic wound healing. 
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CHAPTER 1: PREREQUISITES 
 
1.1. Introduction 
 
This chapter includes the general background information and data 
preprocessing steps that set the stage and serve as prerequisite for remaining 
chapters. We begin by providing an overview of impaired diabetic wound 
healing as a major clinical problem, and highlight recent literature on 
characterization of gene expression dynamic during physiologic and 
pathophysiologic wound healing. Emphasizing various challenges associated 
with analyzing time series gene expression data, we introduce functional data 
analysis (FDA), a relatively young and rapidly developing branch of statistics 
with immense potential to circumvent these challenges. Moreover, we provide 
the necessary statistical and methodological background information related to 
smoothing, a fundamental procedure at the heart of FDA concerned with 
conversion of discrete observations into functional entities. Finally, we introduce 
the microarray data set that will be analyzed throughout this work, and describe 
the preprocessing steps that prepare the raw data for subsequent analyses. 
 
1.2. Impaired diabetic wound healing 
 
Dysfunctional wound healing is a major complication of both type 1 and type 2 
diabetes. Foot ulcerations, which occur in 15% of diabetic patients, lead to over 
82,000 lower limb amputations annually in the United States and cost the 
economy about $153 billion [1, 2]. More importantly, the 5-year mortality rate of 
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a diabetic patient after developing an ulcer is as high as 55% [3]. Majority of 
diabetic foot ulcers are triggered by trauma, but characteristically fail to heal in a 
timely manner and eventually transform into chronic ulcers. While many factors 
contribute to development of diabetic foot ulcers, loss of sensation and poor 
blood supply are the main contributing factors [4]. Compelling evidence suggest 
that chronic diabetic ulcers are staled in an inflammatory state, characterized by 
elevated levels of pro-inflammatory cytokines such as tumor necrosis factor 
alpha (TNF-α) and interleukin 1-beta (IL1-β), as well as matrix 
metalloproteinases (MMP) -8 and -9 responsible for degrading the extracellular 
matrix [5, 6]. Furthermore, a lower ratio of helper (CD4+) to cytotoxic (CD8+) T 
cells and higher infiltration of macrophages have been reported in diabetic ulcers 
compared to acute wounds [7]. Nevertheless, the underlying mechanisms 
contributing to impaired diabetic wound healing are not yet fully understood. 
 
Wound healing is a multifaceted biological process spread over an extended 
period of time, and can be broadly categorized into four highly orchestrated 
overlapping phases: hemostasis, inflammation, proliferation, and remodeling [8]. 
Within seconds post injury, blood-circulating platelets populate the site of injury 
and begin to release stimulatory factors. These factors include inflammatory 
signals to recruit monocytes, as well as components of the coagulation cascade 
such as thrombin to activate fibrin and promote the formation of clot. Long after 
clot formation, monocytes continue to infiltrate the wound bed. Upon 
extravasation and tissue infiltration, monocytes differentiate into macrophages – 
the primary cell of the inflammatory response. Macrophage infiltration and 
	  	  
3	  
activation in response to environmental stimuli is the hallmark of the 
inflammatory phase, and has been shown to play a critical role in determining 
healing outcomes [9]. In addition to phagocytizing bacteria and necrotic tissue, 
macrophages secrete a myriad of inflammatory cytokines and growth factors to 
recruit and regulate other cell types, and thus directly contribute to fundamental 
processes involved in wound healing such as angiogenesis [10]. As the 
inflammatory phase subsides, fibroblast and endothelial cells dominate the 
wound bed to form new tissue. Fibroblasts are mainly responsible for deposition 
of collagen and fibronectin, two major building blocks of extracellular matrix 
(ECM), whereas vascular endothelial cells form new blood vessels to deliver 
oxygen and nutrients to the newly formed tissue [8, 10]. Maturation or tissue 
remodeling is the final phase of wound healing and continues long after wound 
closure. During maturation, the newly deposited tissue, commonly referred to as 
scar, undergoes extensive remodeling so that ECM fibers are realigned properly 
and the physical and mechanical properties of tissue are restored [8, 10]. 
  
More recently, macrophages have emerged as a promising therapeutic target and 
prognostic biomarker in wound repair and regeneration. Use of genetically 
modified mice has allowed researchers to demonstrate the contribution of 
macrophages to different phases of the healing process {Wetzler, 2000 #18}[11, 
12][13]. Macrophages owe this remarkable capacity to their ability to sense and 
respond to various environmental stimuli. Armed with pattern recognition 
receptors (PRR) including Toll-like receptors, wound macrophages sense various 
stimuli present in the wound bed including endogenous stimuli released by 
injured tissue (referred to as damage-associated molecular patterns or DAMPs) 
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and exogenous stimuli released by invading pathogens (referred to as pathogen-
associated molecular patterns or PAMPs) [14]. Activation of PRRs triggers an 
inflammatory signaling cascade leading to expression of pro-inflammatory 
cytokines and cytotoxic activity in macrophages, which is the hallmark of the 
inflammatory phase of the healing process [9, 10]. 
 
Early in vitro studies of macrophage response to activating ligands demonstrated 
that interferon gamma (IFN-g), a potent inflammatory cytokine released by T 
helper type 1 (Th1) cells, enhanced cytotoxic activity of macrophages stimulated 
by bacterial membrane component lipopolysaccharide (LPS) [15]. Unlike IFN-g, 
interleukin-4 (IL-4), a potent anti-inflammatory and T helper type 2 (Th2) 
cytokine, reportedly inhibited macrophage cytotoxic activity and enhanced the 
expression of the mannose receptor [16]. This observation led to coining of the 
term “alternative activation”, to distinguish IL-4-driven response from the 
“classical” IFN-g-driven response. Subsequent studies confirmed that 
macrophage response to environmental cues includes a stimulus-specific 
transcriptional signature that corresponds with the phenotype and function of 
macrophages [17]. Collectively, these findings shaped the M1 and M2 paradigm 
of macrophage activation, as we know it today [18]. In brief, the M1 or classically 
activated category includes the broad spectrum of macrophages inducing 
prototypic inflammatory responses similar to that of IFN-g characterized by 
increased cytotoxic and microbicidal activity, enhanced antigen presentation 
including major histocompatibility complex (MHC) class II expression, and 
increased production of inflammatory cytokines [18, 19]. On the other hand, the 
M2 or alternatively activated category includes the broad spectrum of 
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macrophages antagonizing prototypic inflammatory responses similar to that of 
IL-4 characterized by producing anti-inflammatory mediators such as 
interleukin-1 receptor antagonist, immunoregulatory cytokines such as IL-10, 
and a myriad of growth factors such as platelet-derived growth factor (PDGF) 
and transforming growth factor beta (TGFb) that enhance cellular proliferation 
and tissue deposition [18, 20]. 
 
In spite of its simplistic view, the M1-M2 dichotomy has profound implication in 
wound healing. In early stages of healing, macrophages exhibit an M1-like 
phenotype, secrete pro-inflammatory cytokines, and clear the wound of debris 
and pathogens. As a result of phagocytizing apoptotic cells, in later stages 
macrophages switch to an M2-like phenotype, promote ECM synthesis and 
matrix remodeling, and contribute to angiogenesis [21, 22]. While the precise 
roles of macrophages in wound healing are still poorly understood, it is evident 
that increased number of M2 macrophages is associated with wound healing and 
remodeling, whereas persistent numbers of M1 macrophages coincide with 
impaired healing [23, 24]. Considering the critical role and the therapeutic and 
prognostic potential of macrophages in impaired diabetic wound healing, 
throughout this work we focus on macrophages and their activation states as 
proof of principle to demonstrate how FDA can be utilized to analyze and 
interpret transcriptional response during wound healing in order to address 
specific biological questions. 
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1.3. Genome-wide analysis of transcriptional response during wound healing 
 
High throughput molecular screening technologies such as DNA microarrays 
and RNA-sequencing hold great potential in advancing our understanding of 
wound healing. DNA microarrays convert transcript abundance into an intensity 
measurement that can be used to compare the relative abundance of genes, 
providing a global picture of the molecular and cellular status of the wound [25]. 
Time course studies allow researchers to study dynamic behavior of gene 
expression, and consequently molecular and cellular status, over time. 
 
Several studies have utilized DNA microarrays to study transcriptional response 
during physiologic and pathophysiologic wound healing. Chen et al. used 
microarrays to identify critical differences in skin wounds compared to oral 
mucosal wounds in mouse (GSE23006)[26]. Grice et al. took advantage of genetic 
mouse models to study the interaction between immune response and skin 
microbiota in diabetic skin [27]. Deonarine and colleagues were among the first 
who used genome-wide transcriptional analysis to delineate wound repair in 
healthy human skin at 2, 4, or 8 days post-wounding (GSE5121)[28]. Bronneke et 
al. performed a similar study over an extended period of time to reveal novel 
genes involved in angiogenesis (GSE56803)[29]. In one study Nuutila and 
colleagues used genome-wide expression profiling to investigate the effect of 
negative-pressure therapy on split-thickness skin graft donor site wounds 
(GSE33169)[30]. In two other studies, they further investigated epidermal wound 
healing in these wounds (GSE28914 and GSE50425)[31]. Other studies have 
explored transcriptional response during pathophysiologic wound healing. For 
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instance, Greco et al. reported a microarray analysis of hypertrophic scars in 
thermally injured human skin (GSE8056)[32], whereas Gabriel and colleagues 
reported response of previously healthy human skin to thermal injury as part of 
esthetic scarification (E-MTAB-1323)[33].  
 
Time course gene expression analysis has also been employed to study the role of 
macrophages and determine their activation states during wound healing. 
Deonarine et al. compared the expression of selected M1 and M2 markers at 2, 4, 
or 8 days post-wounding and reported that M2 genes were predominantly up-
regulated at later time point [28]. To better exclude the contribution of 
macrophages to wound healing and inflammation, Cooper and colleagues 
performed microarray analysis in a neonatal macrophage-less (PU.1 null) murine 
wound model where all phases of the repair process are compressed into a 24-
hour period [34]. By comparing the PU.1 null and wild type mice, they linked 
several inflammatory genes at early, mid, and late phases of healing to 
macrophages. More recently, in a pilot clinical study we demonstrated the 
prognostic potential of inflammatory genes derived from in vitro-activated 
macrophages in distinguishing healing vs. nonhealing chronic diabetic foot 
ulcers [35]. In a follow up study, we performed RNA-sequencing on 
macrophages stimulated in vitro with interleukin-10 (IL-10), a potent cytokine in 
scarless wound healing. Dynamic expression of macrophage transcriptional 
signature was then studied over the course of healing in a publicly available 
microarray data set [36]. In agreement with previous findings, we reported up-
regulation of M1-related genes at early stages and M2-related genes at later 
stages during wound healing. Ironically, we also found IL-10 gene signature to 
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be up-regulated at early time points. Collectively, these studies show diverse 
application and potential utility of genome-wide transcriptional analysis to study 
gene expression dynamic during wound healing. Moreover, they emphasize that 
more research is needed to delineate the precise implication of macrophages in 
impaired diabetic wound healing. 
  
Analyzing time series gene expression data, however, remains challenging in 
part due to small sample size, irregularly spaced time points, missing values, 
noisy observations, and high-dimensionality of the data [37]. More importantly, 
the temporal order and potential dependence of observations may introduce 
complex correlation structure in the data, which if ignored can lead to loss of 
information and reduced statistical power [38, 39]. Nevertheless, the vast 
majority of statistical methods available for analyzing gene expression data were 
developed for comparison of unordered categorical conditions, thus ignore the 
order and potential dependence of observations when applied to time series data 
[40]. Furthermore, these methods are often sensitive to irregular sampling, and as 
a result limited in scope [38]. Therefore, there is a substantial need for a statistical 
framework that allows for irregularities in design while accounting for inter-
correlation of observations in time course studies. A natural and fruitful way to 
address this need is to postulate the dynamic process under investigation as a 
smooth function. Discrete observations can then be viewed as noisy realizations 
of this smooth function over time. This idea is at the heart of a branch of 
statistical methods known as functional data analysis. 
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1.4. Functional data analysis 
 
In many disciplines, including biomedical sciences, data is often collected or 
generated through processes that are naturally described as smooth functions. 
Functional data analysis (or FDA for brevity) is the general term referring to a 
class of statistical methods in which smooth functions are treated as statistical 
units [41]. In other words, FDA can be viewed as the practice of analyzing 
smooth functions, or analogously curves. For instance, one may be interested in 
determining major trends of variation among a set of curves, or to compare two 
sets of curves with potentially different mean and variation around the mean, or 
to classify a large group of curves based on their similarity in shape, length, 
curvature, etc. [41]. Functional data may arise in any set up where observations 
are sampled over a continuum such as time or space. In particular, FDA has been 
applied extensively for analyzing time series data in public health and 
biomedical applications [42]. Several characteristics of FDA have contributed to 
its attractiveness. First and foremost, by treating time series data as functions or 
curves, FDA provides a natural and intuitive analytic framework. Second, FDA 
does not require observations to be independent; thereby effectively handling 
complex correlation structures commonly observed in time series data. Third, it 
can be directly applied to studies with irregular time sampling and missing 
values, accommodating irregular designs that are often inevitable in public 
health or biomedical applications. Forth, unlike parametric approaches to 
modeling time series data, FDA does not assume any rigid dependence on time, 
allowing for highly flexible modeling of temporal dynamic, as well as proper 
treatment of the inherent noise in time series data [41-43]. Collectively, by 
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shifting the focus from individually measured values to a functional datum and 
directly utilizing the temporal order and dependence of measurements, FDA 
provides a flexible and powerful approach to study time series data. 
 
In temporal gene expression profiling, samples are collected over time, allowing 
one to study the dynamic behavior of gene expression. Because wound healing is 
a continuous process extended over a period of time, it is crucial to study the 
dynamic expression of genes over the course of healing. The majority of existing 
methods for analyzing high throughput gene expression data have been 
developed with static experiments in mind, and therefore are appropriate for 
comparing unordered categorical conditions (e.g. comparing treatment vs. 
control in a case-control design, or comparing treatment A vs. treatment B vs. 
treatment C in a multi-group design). Static methods are not generally applicable 
to time series data with unbalanced designs. Moreover, static methods fail to 
properly use the temporal structure of data, either leading to loss in power or 
incorrect inference [38]. Functional methods, on the contrary, provide a natural 
and fruitful way to circumvent the limitations of static methods (e.g. in handling 
irregularly spaced time points and missing values), while taking into account the 
temporal order and potential dependence of observation. The advantages of 
functional methods over conventional static methods have been extensively 
highlighted in the literature on analyzing time series gene expression data. For 
example see the work of Storey et al. [38], in particular Supporting Appendix on 
“Why Static Sampling Methods are Problematic for Time Course Analyses”, or 
the work of Berk et al. on analyzing longitudinal gene expression data [44]. 
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In fact, Storey et al. were among the first who combined FDA with likelihood 
ratio statistic for differential expression analysis [38]. Since then, several studies 
have explored different flavors of FDA to perform differential expression 
analysis [39, 45, 46]. Berk and colleagues extended the work of Storey et al. and 
proposed an L2-norm-based statistic to assess differential expression [44]. Chen 
et al. applied functional principal component analysis to identify differentially 
expressed genes in time series microarray data [47]. Other studies have explored 
FDA for clustering [48-50] or gene set testing [46, 51]. More recently, FDA-based 
methods have also been applied for differential expression analysis of time series 
RNA-sequencing count data [52-54]. Regardless of the goal of analysis (whether 
it be identifying differentially expressed genes, clustering genes based on their 
temporal pattern, or gene set testing) the central theme in FDA is to treat 
functional observations as a single datum rather than a set of discrete 
observations. Estimating a continuous curve from discrete measurements 
observed over a continuum is a fundamental step at the core of FDA also known 
as smoothing. 
 
1.4.1. Smoothing 
 
In functional approaches to analyzing time series data, the underlying process is 
postulated as a smooth function over time. Discrete observations are then viewed 
as noisy realizations of this smooth function. Smoothing appears particularly 
intuitive in applications where the phenomenon under investigation is perceived 
as a continuous process (e.g. gene expression over time), and thus can be 
represented by smooth curves. More formally, the objective of smoothing is to 
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remove noise from observations to obtain a smooth estimate of the trend of a 
response variable 𝑌 as a function of one or more predictor variables 𝑋!,𝑋!,… ,𝑋! 
                                                                                             𝑓(𝑋!,𝑋!,… ,𝑋!) = 𝐸 𝑌 𝑋!,𝑋!,… ,𝑋!                                                                         (1.1) 
 
Since we are interested in estimating gene expression as a function of time, we 
limit our discussion to the single predictor case, commonly referred to as 
scatterplot smoothing, i.e. 
                                                                                             𝑓 𝑡𝑖𝑚𝑒 = 𝐸 𝑔𝑒𝑛𝑒  𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑡𝑖𝑚𝑒                                                                       (1.2) 
 
What distinguishes scatterplot smoothers from parametric regression methods is 
that no rigid form is assumed in estimating gene expression as a function of time. 
This flexibility is extremely appealing in modeling highly dynamic trends where 
shape of 𝑓 or form of dependence of gene expression on time is not known a 
priori. Several competing approaches exist for smoothing: smoothing by basis 
function expansion such as regression splines, smoothing by local polynomial 
regression and local weighting (i.e. kernel smoothers), and smoothing by 
roughness penalty such as smoothing splines [41, 55]. Each smoothing approach 
has its own devotees, and can be effectively applied in a variety of applications. 
Although the choice of smoothing method is a matter somewhat of individual 
taste and background, in practice the nature of data and the objective(s) of 
analysis often influence the choice of smoothing procedure [56]. 
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In the basis function approach, the smooth fit is parameterized as a linear 
combination of basis functions (e.g. Fourier basis, polynomial basis, wavelet 
basis, etc.) and obtained via minimization of a residual sum of squares criterion. 
The critical decisions in basis function approach are the choice of basis function 
(typically chosen in harmony with known characteristics of the underlying 
process generating the data), and the number and location of knots. Because the 
extent to which the data are smoothed is dictated by the number and location of 
knots, basis function approach has clumsy and discontinuous control over the 
degree of smoothing [41]. Consequently, in whole-genome transcriptome 
analysis where smoothing is to be performed on thousands of genes with very 
heterogeneous expression profiles (i.e. optimal number and location of knots 
identified for one gene may not suit another gene), the basis function approach 
becomes extremely cumbersome. 
 
In the local weighting approach to smoothing, the local dependence of the 
estimated fit at a given point 𝑡 on the observations near 𝑡 is made more explicit 
by means of local weight functions (also known as kernels) or local regression 
(typically using polynomials of degree 1 or 2 in the vicinity of point 𝑡). Kernel 
smoothing and local polynomial fitting techniques are easy to understand and 
have excellent computational characteristics. The Locally Weighted Scatterplot 
Smoothing or LOWESS introduced in [57] is a popular example of local 
weighting approach to smoothing. On the negative side, at a given point 𝑡 in 
time, the local weighting approach by definition relies on the immediate 
neighborhood of 𝑡, and thus requires densely sampled data. This requirement is 
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often not met in time course genomic data. For the same reason, the local 
approach is also instable near the boundaries of the time interval. Given the 
limited number of time points and the biological importance of boundary values, 
smoothing by local weighting or local regression is not popular in analyzing time 
course microarray data. Furthermore, even though smoothing by local weighting 
offers continuous control of the smoothness of the fit, these scatterplot smoothers 
are seldom formulated as solutions to explicit statistical problems. As a result of 
this heuristic nature, no explicit formula is returned for the resultant smooth fit, 
making downstream analysis (e.g. testing for the interaction effects between 
covariates) and extension to other smoothing situations (e.g. modeling subject-
specific curves in longitudinal studies) difficult.  
 
The roughness penalty approach, on the other hand, retains the advantages of 
basis function and local smoothing procedures while addressing some of their 
limitations. Similar to basis expansion approach, the roughness penalty approach 
is based on explicit formulation of the smooth fit including the smoothness 
criterion, which can be readily used in downstream analyses. More importantly, 
the roughness penalty approach adapts elegantly to more general smoothing 
problems than simply estimating a curve from observations. For example, the 
roughness penalty approach can be used to estimate subject-specific curves in 
longitudinal studies [38, 44], or to obtain smooth functional principal 
components [41]. 
 
Common practical criteria for evaluating and deciding between scatterplot 
smoothers include but are not limited to convenience, implementability, 
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flexibility, simplicity, tractability, reliability, efficiency, and extendibility [56]. 
Based on the nature of time course microarray data, we gave more weight to 
implementability and extendibility and thus opted for the roughness penalty 
approach to smoothing via cubic smoothing splines. Our choice is further 
supported by the overwhelming majority of the literature on application of FDA 
to time course transcriptome data as cited throughout this work. 
 
1.4.1.1. Cubic smoothing splines 
 
An intuitive approach to smoothing is to think of gene expression measurements 
in terms of signal and noise, i.e. 
                                                                               𝑑𝑎𝑡𝑎 = 𝑠𝑖𝑔𝑛𝑎𝑙 + 𝑛𝑜𝑖𝑠𝑒   or   𝑦! = 𝑓 𝑡! + 𝜀!                                                             (1.3) 
 
where 𝑦! indicates gene expression at time point 𝑡!, 𝑓 is true signal representing 
the underlying smooth curve, and 𝜀! are independent and identically distributed 
(i.i.d.) random variables representing technical or biological noise. Here we 
assume independent sampling, in which gene expression measurements are also 
i.i.d.; The general case with dependent observations will be discussed later. The 
goal of smoothing then is to estimate the smooth function 𝑓 𝑡  that captures 
signal by minimizing noise subject to certain smoothing condition. From a 
mathematical standpoint, this smooth function can be described as the solution 
to a minimization problem over all m-times differentiable functions 𝑓 [41]: 
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                                                                                            min 𝑦! − 𝑓 𝑡! !! + 𝜆 𝑓(!) !                                                                       (1.4) 
 
where 𝜆 is a tuning parameter and f (!) is the 𝑚!! derivative of 𝑓 . The solution to 
this minimization problem is called smoothing splines smoother of degree 2𝑚 − 1. Typically, we take 𝑚 = 2, in which case the solution is referred to as 
cubic smoothing splines. In the above formula, the first term {𝑦! − f 𝑡! }!!  is the 
residual sum of squares that quantifies how well f 𝑡  fits the data. The second 
term 𝜆 (f (!))! is a penalty term, which penalizes the curvature and as a result 
regulates the smoothness of the fit. The smaller the value of 𝜆, the smaller the 
penalty term and the jumpier the fit. In fact, if 𝜆 = 0, f t  will exactly interpolate 
all data points. As the value of 𝜆 increases, f t  is encouraged to be smoother. 
Eventually, as 𝜆 → ∞, f t  represents a perfectly smooth straight line passing as 
closely as possible through data points. In other words, the smoothing parameter 
adjusts the trade off between bias and variance of the fit. Figure 1 shows the 
natural cubic smoothing splines fit to simulated data with different values for the 
tuning parameter 𝜆. 
 
It is evident that the choice of tuning parameter 𝜆 is critical in determining the 
smoothness of the fit. A common approach for automatic selection of the 
smoothing parameter 𝜆  is cross-validation (CV) or its less computationally 
intensive analog, generalized cross-validation (GCV) [58]. The idea behind CV is 
to leave points (𝑡! ,𝑦!) out one at a time, and estimate the smooth at 𝑡! based on hj
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Figure 1. The effect of smoothing parameter on cubic smoothing fit. A) Simulated data based on 
sine curve. B) Interpolation fit when lambda is set to zero. C-E) As lambda increases the noisy 
fluctuation of the curve decreases. Panel C shows under-smoothing due to small lambda; panel D 
shows an optimal smooth curve; and panel E shows over-smoothing due to very large lambda. 
 
the remaining points. The sum of squares of CV is then calculated as: 
 
                                                                                                          𝐶𝑉 𝜆 = 1𝑛 𝑦! − 𝑓!!! 𝑡! !!!!!                                                                                         (1.5) 
 
where 𝑓!!! 𝑡!  is the fit at 𝑡! obtained by leaving out 𝑖!! data point. In practice, 𝐶𝑉 𝜆  is computed for a range of values of 𝜆 to select the minimizing 𝜆. Smooth 
curve in panel D of Figure 1 was indeed obtained using GCV. Among alternative 
methods for automatic selection of smoothing parameter such as Mallows’ 𝐶! 
statistic and information criterion measures (AIC and BIC), mixed model 
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approach is extremely appealing for several reasons [56]. First, in the mixed 
model approach, smoothing parameters become variance components, allowing 
the wealth of mixed model methodology and software to be used for smoothing 
[56]. Second, likelihood-based estimation of smoothing parameter tends to be 
more robust than its counterparts. For example, it has been shown that at finite 
sample sizes (which is generally the case in time course gene expression studies), 
GCV and AIC are prone to under-smoothing, while 𝐶! and BIC tend to over-
smooth the data [59, 60]. Third, and perhaps the most important from a practical 
standpoint, the mixed model approach allows for easy incorporation of 
covariates including additional random variables capturing inter-correlation 
among longitudinal observations. Throughout this work we use the mixed 
model approach to smoothing, which is briefly reviewed next. 
 
1.4.1.2. Linear mixed model 
 
Mixed models are extension of regression models capable of incorporating 
random effects. A general linear mixed model with arbitrary design matrix can 
be presented as 
                                                                                                                                   𝑦 = 𝑋𝛽 + 𝑍𝑢 + 𝜀                                                                                                              (1.6) 
 
where 𝛽 is a vector of fixed effects, 𝑢 is a vector of random effects, 𝑋 and 𝑍 are 
design matrices of covariates such that 𝐸 !! = !! , 𝐶𝑜𝑣 !! = !! !! , and 𝑉 ≡𝐶𝑜𝑣 𝑦 = 𝑍𝐺𝑍! + 𝑅. Consequently, textbook estimator of 𝛽 and 𝑢 are 
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                                                                                            𝐵𝐿𝑈𝑃 𝛽 ≡ 𝛽 = 𝑋!𝑉!!𝑋 !!𝑋!𝑉!!𝑦                                                                      (1.7)                                                                                                 𝐵𝐿𝑈𝑃 𝑢 ≡ 𝑢 = 𝐺𝑍!𝑉!! 𝑦 − 𝑋𝛽                                                                               (1.8) 
 
where BLUP stands for best linear unbiased prediction. Importantly, it can be 
shown that finding (𝛽,𝑢) involves minimization of the penalized least squares 
criterion also known as ridge regularization [56] 
                                                                            𝑦 − 𝑋𝛽 − 𝑍𝑢 !𝑅!! 𝑦 − 𝑋𝛽 − 𝑍𝑢 + 𝑢!𝐺!!𝑢.                                                        (1.9) 
 
from which the BLUP of (𝛽,𝑢) can also be expressed as 
 
                                                                                                   𝛽𝑢 = (𝑊!𝑅!!𝑊 + 𝐾)!!𝑊!𝑅!!𝑦                                                                          (1.10) 
 
where 𝑊 ≡ 𝑋  𝑍  and 𝐾 ≡ 0 00 𝐺!! . 
 
It is evident that BLUPs of 𝛽  and 𝑢  depend on 𝐺 = 𝐶𝑜𝑣 𝑢  and 𝑅 = 𝐶𝑜𝑣 𝜀 . 
Maximum likelihood (ML) or restricted maximum likelihood (REML) are the 
most common strategies for estimating parameters in the covariance matrix (𝑉). 
The log-likelihood of 𝑛 observations under the model 𝑦~𝑁(𝑋𝛽,𝑉) is  
 
                                              𝑙 𝛽,𝑉 = − 12 𝑛𝑙𝑜𝑔 2𝜋 + log 𝑉 + 𝑦 − 𝑋𝛽 !𝑉!! 𝑦 − 𝑋𝛽                         (1.11) 
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For a fixed V, 𝑙 𝛽,𝑉  is maximized over 𝛽 by 𝛽 given by 𝐵𝐿𝑈𝑃 𝛽 . Substituting 𝛽 
by its BLUP estimator in (1.11) yields the profile log-likelihood for 𝑉, 𝑙! 𝑉  
 
𝑙! 𝑉 = − 12 𝑛𝑙𝑜𝑔 2𝜋 + log 𝑉 + 𝑦 − 𝑋𝛽 !𝑉!! 𝑦 − 𝑋𝛽                                            = − 12 log 𝑉 + 𝑦!𝑉!! 𝐼 − 𝑋 𝑋!𝑉!!𝑋 !!𝑋!𝑉!! 𝑦 − 𝑛2 log 2𝜋                 (1.12) 
 
Similarly, the restricted log-likelihood for 𝑉 is 
 
                                                                                                      𝑙! 𝑉 = 𝑙! 𝑉 − 12 log 𝑋!𝑉!!𝑋                                                                               (1.13) 
 
The difference between REML and ML is that REML takes the degrees of 
freedom of the fixed effects into account, and thus returns unbiased estimates for 
variance components [56]. 
 
1.4.1.3. Penalized splines as BLUPs 
 
An alternative approach to arrive at smoothing splines is the general framework 
of penalized splines. Let us consider the simulated data of Figure 1. Let us 
further assume that 𝑦! = 𝑓 𝑡! + 𝜀! and 𝐶𝑜𝑣 𝜀 = 𝜎!!𝐼. A simple parameterization 
of 𝑓 𝑡  would be via a straight line as shown in Figure 2A, i.e. 
                                                                                                                               𝑦! = 𝛽! + 𝛽!𝑡! + 𝜀!                                                                                                         (1.14) 
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where the term 𝛽! + 𝛽!𝑡! is a linear combination of the basis functions 1 and 𝑡. In 
general, a basis of a vector space is a set of elements from that space such that 
any element of the space can be expressed as the linear combination of basis 
elements. In matrix form, (1.14) can be written as 
                                                                                                                                           𝑦 = 𝑋𝛽 + 𝜀                                                                                                                    (1.15)   
 
where 𝑦 is an n×1 vector of response variables, 𝜀 is an n×1 vector of errors, and X 
is an n×2 matrix of predictor variables. In this case, columns of X correspond to 
basis functions 
 
𝑋 = 1 𝑡!⋮ ⋮1 𝑡! . 
 
Furthermore, the least square estimate of 𝛽 is 
                                                                                                                                   𝛽 = (𝑋!𝑋)!!𝑋!𝑦,                                                                                                      (1.16) 
 
and the fitted values can be obtained by 
                                                                                                                               𝑦 = 𝑋(𝑋!𝑋)!!𝑋!𝑦.                                                                                                      (1.17) 
 
One possible extension of (1.14) is to consider a model such as the one shown in 
Figure 2B, with two linear fits joint at 𝑡 = 1.5 , about which the trend of 
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observations appears to change. To formulate this new model in terms of basis 
functions, we can introduce a new basis function that is zero to the left of 𝑡 = 1.5, 
and a positively sloped function from 𝑡 = 1.5 onward 
                                                                                           𝑦! = 𝛽! + 𝛽!𝑡! + 𝛽!! 𝑡! − 1.5 ! + 𝜀!                                                                            1.18  𝑤ℎ𝑒𝑟𝑒         𝑡! − 1.5 ! = 0                                𝑖𝑓  𝑡! < 1.5𝑡! − 1.5          𝑖𝑓  𝑡! ≥ 1.5     
 
We say that 𝑡! − 1.5 ! is a truncated line, and that the model has a break point 
or “knot” at 𝑡 = 1.5 where the two lines are tied. It is easy to see that this new 
model can be fit using (1.15) with 
 
𝑋 = 1 𝑡! (𝑡! − 1.5)!⋮ ⋮ ⋮1 𝑡! (𝑡! − 1.5)! . 
 
A model such as (1.18) is called a linear spline model, and a function such as 𝑡! − 1.5 ! is called a linear spline basis function. Adding additional knots to 
(1.18) is straightforward. Figures 2C-D show alternative models with 3 and 5 
internal knots fit to the same data. The general linear spline model for 𝑓 is 
 
                                                                                                  𝑓 𝑡 = 𝛽! + 𝛽!𝑡 + 𝑢! 𝑡 − 𝜉! !!!!!                                                                          1.19  
 
where 𝑓 is a piecewise linear function with internal knots at 𝜉! , 𝑗 = 1,… , 𝐽. 
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Figure 2. The effect of position and number of knots on linear spline fit. A) Linear spline fit to 
simulated data with no internal knot. Linear spline fit with B) one internal knot at t=1.5, C) two 
internal knots at t=1 and t=2.25, and D) five internal knots at t=1, 1.5, 2, 2.5, and 3.   
 
When the form of the underlying function is not known, knot selection can 
become challenging. While in our simulated data increasing the number of knots 
improved the fit, this is not always the case since having too many knots could 
lead to overfitting as shown in Figure 1.B. In a data set with 𝐾 candidate knots, 
there will be 2!  possible models with the intercept and all linear terms 
considered. Therefore, conventional model selection strategies quickly become 
impractical for knot selection as the number of knots increases. An alternative 
approach is to keep all knots in the model, but constrain their influence on the fit. 
This is very much in line with the smoothing spline approach introduced earlier. 
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For the general linear spline model of (1.19), the ordinary least-squares (OLS) fit 
can be written as 𝑦 = 𝑋𝛽 , where 𝛽  minimizes ||𝑦 − 𝑋𝛽||! , in which | 𝑊 | =𝑊!𝑊  is the length of the vector 𝑊 , and 𝛽 = [𝛽!,𝛽!,𝛽!!,… ,𝛽!!]!  with 𝛽!! 
representing the coefficient of the 𝑗!! knot. One way to constrain coefficients 𝛽!! 
is to assume a ridge-like penalty term by imposing an upper limit on their sum of 
squares, i.e. 𝛽!!! < 𝐶. Then the minimization problem can be written as 
 
                                    min  (||𝑦 − 𝑋𝛽||!)   subject to   𝛽!𝐷𝛽 ≤ 𝐶                                                            (1.20) 
 
where 𝐷 is a 𝐽 + 2 × 𝐽 + 2  matrix defined as 𝐷 = 0!×! 0!×!0!×! 𝐼!×! . Using Lagrange 
multiplier, it can be shown that (1.20) is equivalent to 
                                                                         min  (||𝑦 − 𝑋𝛽||! + 𝜆!𝛽!𝐷𝛽)   for some   𝜆 ≥ 0.                                                (1.21) 
 
where the term 𝜆!𝛽!𝐷𝛽  is called “roughness penalty”, as it penalizes the 
roughness of the fit. The minimization problem (1.21) has the unique solution 
                                                                                                                   𝛽! = 𝑋!𝑋 + 𝜆!𝐷 !!𝑋!𝑦                                                                                            (1.22) 
 
Therefore, for a given 𝜆, the fitted values of a penalized linear spline fit can be 
obtained by 
                                                                                                                 𝑦 = 𝑋 𝑋!𝑋 + 𝜆!𝐷 !!𝑋!𝑦                                                                                            (1.23) 
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In the penalized spline estimation of (1.19), if we let 𝛽 = 𝛽!𝛽!  and 𝑢 = 𝑢!⋮𝑢! , and 
define 𝑋 = 1 𝑡!⋮ ⋮1 𝑡!  and 𝑍 = 𝑡! − 𝜉! ! … 𝑡! − 𝜉! !⋮ ⋱ ⋮𝑡! − 𝜉! ! … 𝑡! − 𝜉! ! , the penalized spline 
fitting criterion (1.21) divided by 𝜎!! can be written as 
 
                                                                                                       1𝜎!! ||𝑦 − 𝑋𝛽 − 𝑍𝑢||! + 𝜆!𝜎!! ||𝑢||!.                                                                              (1.24) 
 
By treating 𝑢 as a set of random coefficients with 𝐶𝑜𝑣 𝑢 = 𝜎!!𝐼, where 𝜎!! = !!!!!, 
(1.24) would be equivalent to (1.9), leading to mixed model representation of 
penalized spline 
 
𝑦! = 𝑓 𝑡 + 𝜀! = 𝛽! + 𝛽!𝑡 + 𝑢! 𝑡 − 𝜉! ! +!!!!   𝜀! 
𝑦 = 𝑋𝛽 + 𝑍𝑢 + 𝜀,    𝐶𝑜𝑣 𝑢𝜀 = 𝜎!!𝐼 00 𝜎!!𝐼       𝑎𝑛𝑑      𝜆! = !!!!!! 
 
Although for simplicity, we limited above discussion to linear splines, extension 
of spline model (1.19) to general degree 𝑝 is straightforward. Using the truncated 
power basis of degree p 
 1, 𝑡,… , 𝑡!, 𝑡 − 𝜉! !! ,… , 𝑡 − 𝜉! !! , 𝑡 − 𝜉! !!    
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the 𝑝!! degree spline model is 
 
                                                                      𝑓 𝑡 = 𝛽! + 𝛽!𝑡 +⋯+ 𝛽!𝑡! + 𝛽!" 𝑡 − 𝜉! !!!!!!                                                   (1.25) 
 
Throughout this work we set p=3, and hence work with cubic splines. 
Furthermore, in practice power functions of the form 𝑡 − 𝜉! !! , where 𝑝 = 1, 2,…, 
are not numerically stable. As a result software implementation of the OLS fitting 
of spline models is usually based on alternative basis functions with more stable 
numerical properties [56]. 
 
Finally, the mixed model representation of penalized spline fit can be easily 
modified to account for inter-correlation among longitudinal measurements 
observed in the same individual. The model 𝑦! = 𝑓 𝑡! + 𝜀! can be extended by 
taking 𝑓 𝑡!  to be additive sum of two components 
                                                                                                                     𝑓 𝑡!" = 𝑢 𝑡!" + 𝜈! 𝑡!"                                                                                             (1.26)  
 
where 𝑢 𝑡!"  represents the population average curve, and 𝜈! 𝑡!"  represents 
individual-specific curves for 𝑗 = 1, 2,…   𝐽 individuals. Of note, both 𝑢 𝑡!"  and 𝜈! 𝑡!"  are considered smooth functions of time, however 𝑢 𝑡!"  is treated as a 
fixed yet unknown curve, whereas 𝜈! 𝑡!"  are treated as random realizations of a 
Gaussian process. Penalized spline parameterization of 𝑢 𝑡!"  and 𝜈! 𝑡!" , as 
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discussed above, leads to general mixed model formulation of (1.6) well-suited 
for analyzing time series gene expression data that are short, noisy, and exhibit 
repeated measures correlation [44]. 
 
1.5. Data set  
 
The objective of this work was to implement a comprehensive functional 
methodology to investigate temporal dynamic of gene expression during 
impaired diabetic wound healing. To this end, we used a previously reported 
time series microarray data set on impaired cutaneous wound healing in a 
murine model of diabetes [27]. The study by Grice et al. used genetically diabetic 
mice that were deficient for the leptin receptor (𝐿𝑒𝑝𝑟  !"/!"). Leptin is a hormone 
produced by fatty cells, and a key regulator of appetite and energy homeostasis. 
The db/db mice are homozygous for a point mutation in the gene coding for the 
leptin receptor, and thus exhibit many features of obesity and type 2 diabetes 
[61]. As a result, the db/db mice exhibit severe and impaired wound healing 
compared to other diabetic murine models, and have been used extensively to 
study impaired diabetic wound healing. 
 
In brief, to establish baseline for gene expression, unwounded skin was collected 
from db/db mice and heterozygous controls (db/+) using skin punch biopsies. 
To investigate transcriptional response during healing, a 6mm full-thickness 
excisional wound was created on the back of each mouse, and 2mm skin biopsies 
were collected at the wound margin at 3, 7, 14, and 21 days post wounding. At 
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each time point, samples were obtained from n=4 mice of each genotype (except 
for day 14 with n=3 db/+ mice), and whole-transcriptome profiling was 
performed using GeneChip 430 2.0 mouse arrays by Affymetrix. Of note, the 
focus of the study by Grice et al. was to characterize the microbial community 
that colonizes diabetic wounds, and to assess the shift in microbiome over the 
course of healing in db/db wounds compared to db/+ controls. The authors 
limited analysis of the microarray data to a small portion of genes defined by 
three overlapping Gene Ontology terms: immune response, defense response, 
and response to wounding; and explored temporal correlation between selective 
shift in microbiome and aberrant gene expression in db/db vs. db/+ wounds. 
Consequently, a vast pool of information contained in this microarray data set is 
yet to be explored. 
 
1.6. Data Preparation 
 
Microarray data was kindly provided by Dr. Elizabeth Grice from the University 
of Pennsylvania. Data had been normalized using the standard method of robust 
multi-array analysis (RMA), as described in the original publication [27]. First, 
we assessed the quality of normalized data using Bland-Altman plots (aka MA-
plots) and global assessment of intensity values as previously described [62]. 
Figure 3 shows global distribution of intensity values for all 39 arrays, 
confirming adequate normalization. While within- and between-array 
normalization reduce technical variability by adjusting global properties of 
measurements, they do not address unwanted systematic heterogeneity 
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Figure 3. Global distribution of normalized intensity values. Under the assumption that majority 
of genes are not differentially expressed, global distribution of intensity values are expected to be 
similar among all arrays. A) Boxplot of intensity values (log2 scale) for each of 39 arrays. B) 
Histogram of intensity values (log2 scale) demonstrating a characteristic bimodality of RMA-
normalized intensity values. 
 
commonly referred to as batch effects [63]. Batch effects are ubiquitous in high 
throughput genomic studies and if left untreated can adversely affect 
downstream results by obscuring true modes of variation in data. Therefore, we 
next explored the potential existence of batch effects using the method of 
surrogate variable analysis (SVA) from Bioconductor [64]. In brief, SVA 
represents a class of batch correction methods that attempt to identify potential 
batch effects using a data-driven factor analysis as opposed to methods that 
correct for known batch using linear modeling [65]. In SVA, first the primary 
signal is regressed out of the data. The residual matrix is then decomposed into 
orthogonal singular vectors using singular value decomposition. These singular 
vectors are tested for significance via permutation to guarantee that they are not 
associated with variables of interest. Next, for each significant singular vector a 
subset of highly associated genes is identified, taking into consideration the fact 
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that each singular vector (unwanted factor) may affect only a subset of genes. A 
surrogate variable is then generated from the original data based on each 
identified subset of genes, allowing for correlation between surrogate variables 
and variables of interest. Identified surrogate variables are subsequently 
implemented in downstream analyses as additional covariates to account for 
unwanted systematic variation in the data [64, 65]. 
 
After SVA, exploratory data analysis was performed to compare the overall 
patterns of expression, as well as the contribution of time and genotype to 
variation observed among arrays. First, hierarchical clustering was performed 
using Ward’s minimum variance method [66], in which the objective function 
during the agglomerative clustering procedure is to minimize the ratio of within-
cluster to between-cluster variance. Figure 4 shows the resulting clustering 
dendrogram. It is evident that unwounded skin (day 0) in both genotypes (db/+ 
and db/db) clustered together and away from the rest of the samples. Arrays at 
later time points were further split in two main clusters depending on whether 
they presented mid or late time points. Interestingly, in agreement with healing 
rates measured by change in wound size, db/db wounds on day 7 clustered with 
wounds on day 3 from both genotypes, suggesting a delay in healing of db/db 
wounds compared to db/+ controls. Same trend was observed at later time 
points, where db/db wounds on days 14 and 21 also clustered with db/+ 
wounds on day 7. Further corroborating visual observation of wound status 
reported by Grice et al., global gene expression patterns were found to be more 
identical at later time points (days 14 and 21) within each genotype. 
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Figure 4. Clustering dendrogram of processed microarray data. Y-axis demonstrates the 
Euclidean distance between arrays. Agglomerative clustering was performed using Ward’s 
minimum variance method. 
 
Next, we performed principal component analysis (PCA) to assess the 
contribution of time and genotype to overall variation observed among arrays. 
Based on the plot of eigenvalues versus principal components (a.k.a. scree plot), 
we took the first three principal components (PC) capturing 71% of total 
variation among arrays. Figure 5 demonstrates the scatterplot matrix of the first 
three PC scores for all 39 arrays. To further inspect the association of PC scores 
with factors of interest, i.e. time and genotype, we also made boxplots of PC 
scores versus these two factors. Overall, with PC1 and PC2 capturing time-
related variability, and PC3 capturing the effect of genotype on overall variation 
among arrays, PCA confirmed temporal patterns revealed by clustering. 
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Figure 5. Principal component analysis (PCA) of processed microarray data depicting main 
directions of variability among all 39 arrays. A) Scatterplot matrix of first three principal 
components capturing 37, 27, and 7 percent of overall variation, respectively. B) Boxplot of PC 
scores versus time and genotype. 
 
downstream analyses, we converted intensity data from probe-level to gene-level 
using Affymetrix Mouse Genome 430 2.0 Array annotation data (mouse4302.db) 
from Bioconductor [67]. We further excluded uninformative or ambiguous 
probes for which either no mapping was available or more than one mapping 
was reported. Also, in case of many-to-one mapping of probe- to gene-ids, the 
probe with largest coefficient of variation across all 39 arrays was retained. 	  
 
Throughout this work, intensity measurements summarized at the gene-level 
will be used as input for smoothing. Several software implementation of 
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smoothing splines exist. Basic functionality of R statistical software includes an 
implementation of cubic smoothing splines with CV or GCV for automatic 
selection of smoothing parameter. The R package SME implements mixed-effect 
smoothing splines approach using AIC/BIC for automatic selection of smoothing 
parameter [44]. The R package mgcv, which we rely on for smoothing in this 
work, also provides a variety of smoothing functionalities including mixed-effect 
smoothing splines with ML or REML for automatic selection of smoothing 
parameter [68]. 
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CHAPTER 2: FUNCTIONAL DIFFERENTIAL VARIATION ANALYSIS 
 
2.1. Introduction 
 
In previous chapter, smoothing splines were introduced as the solution to 
minimization of a residual sum of squares criterion subject to a smoothness 
penalty. It was further demonstrated that formulating smoothing splines as 
BLUP of a mixed model facilitates identification of smoothing parameter using 
the statistical methodology of mixed models, especially when there is 
dependence between observations. Building on this framework, in this chapter 
we begin our analysis of transcriptional response during impaired diabetic 
wound healing by investigating the temporal dynamic of individual genes. 
  
An essential step in genome-wide expression profiling is to identify genes that 
exhibit changes in expression under experimental conditions. The overarching 
goal of differential expression analysis is to identify relevant genes that may 
serve as biomarkers and reveal potentially novel insight into the complex biology 
of the phenomenon under investigation. In a static design with two or more 
experimental groups, the aim of differential expression analysis is to identify 
genes that are uniquely up- or down-regulated in one group or exhibit similar 
patterns among different groups. In a time course design, the interest is typically 
in temporal variation of gene expression; hence differential variation analysis. 
Similarly, the aim of differential variation analysis is to identify genes that 
exhibit temporal dynamic (i.e. are not stable over time) within a single group, or 
have distinct patterns between two or more groups.  
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Classical methods of differential expression analysis rely on t-test or analysis of 
variance (ANOVA), and variations thereof, which generally suit comparison of 
categorical conditions. While in practice one may ignore the temporal order and 
spacing of observations and treat each time point as a separate biological 
condition, applying these tests to time series gene expression data requires the 
study to have a balanced design. However, in reality more often than not this 
condition is not met, leaving experimenters with two equally unsatisfying 
options beside imputation procedures to make the design nearly balanced: 1) to 
pool conditions, or 2) to exclude observations that are not in temporal harmony 
with the majority of observations. For instance, in a microarray study of 
thermally injured human skin, Greco et al. pooled skin biopsies collected over a 
range of time points into three categories (0-3 days, 4-7 days, and >7 days), 
thereby treating time as a categorical predictor with three levels in an ANOVA of 
differential expression [32]. In another study comparing temporal dynamic of 
selected genes in longitudinal biopsies of chronic diabetic foot ulcers, two-third 
of patients had to be excluded from downstream analysis due to large number of 
observations with unmatchable time points [35]. 
 
These examples highlight practical limitations of analyzing time series gene 
expression data using methods that are incapable of handling irregularities 
commonly observed in time course studies. It is further evident that ignoring the 
temporal order and spacing of observations may lead not only to loss of 
information and statistical power to discover time-related trends (as in example 
1), but also to waste of resources (as in example 2). 
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Functional data analysis (FDA) provides an effective solution to circumvent 
challenges associated with analyzing time series gene expression data. Storey et 
al. were among the first who proposed a functional approach to differential 
variation analysis using spline-based methods [38]. In brief, for each gene a 
smooth curve was fit to expression values using a p-dimensional natural cubic 
spline, where p was a single value for all genes obtained from singular value 
decomposition (SVD) of expression data. Furthermore, the authors allowed for 
dependence between observations when the study involved longitudinal 
sampling by incorporating random effects in the model. Finally, separate models 
were fit to expression data under the null and alternative hypotheses, and an F-
type statistic was computed based on the increase in goodness of fit to assess 
differential variation. Another functional approach to differential variation 
analysis is based on functional principal component analysis (FPCA). 
Multivariate principal component analysis (PCA) is a well-known dimension 
reduction technique that is used extensively in analysis of gene expression data. 
FPCA is an extension of PCA to functional data, allowing for parameterization of 
smooth curves using eigenfunction basis expansion [41]. Two separate studies by 
Liu et al. [69] and Wu et al. [70] applied FPCA to model gene expression dynamic 
and used an F-type statistic similar to that of Storey et al. for hypothesis testing.    
 
Although promising, these approaches had some limitations. First, selecting the 
dimension of spline fit based on SVD or basis expansion up to a few principal 
functions will inevitably lead to over-smoothing in some genes and under-
smoothing in the others. Second, Storey et al. modeled individual-specific 
deviations from population mean curve with random scalars corresponding to 
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vertical shifts from the mean curve. While this assumption appeared to be 
justified in the example data set analyzed by the authors, it is not valid in general 
and therefore may not properly capture the heterogeneity of individual-specific 
curves. Similarly, incorporating repeated measures correlation is not 
straightforward in FPCA. Analogous to multivariate PCA, in FPCA it is 
generally assumed that observations are independent, as it was the case in the 
work of Liu et al and Wu et al. To address these limitations, Berk et al. proposed 
smoothing splines mixed effect modeling of longitudinal gene expression data 
[44]. Given the shortness of time series (typically less than 10 time points) and 
limited number of replicates, the authors opted for smoothing splines, in which 
the number of knots is set equal to unique number of time points. Moreover, 
individual-specific deviations were modeled as smooth functions of time 
allowing for higher flexibility of the model, and the population and individual-
specific smoothing parameters where determined using likelihood-based criteria. 
Having obtained a smooth curve for each individual, Berk et al. then employed 
an L2-norm-based statistic to quantify the difference between two sets of curves 
while taking into account the within-group variability obtained from individual-
specific curves. 
 
These methods are similar in spirit to classic mixed model approach to analyzing 
longitudinal data, whereby the dependence of response variable on time is 
modeled linearly or via some parametric nonlinear model [56]. Two advantages 
of spline-based mixed models (such as those put forward by Storey et al. and 
Berk et al.) over classic mixed models are worth noting. First, by adopting the 
spline parameterization, we do not make any prior assumption on the nature of 
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the dependency of response variable on the continuous predictor. Instead we 
allow the data to speak for itself and the nature of the dependencies to be 
determined via the fixed and random effects in the mixed model representation 
of the spline fit. This flexibility is key in modeling highly dynamic processes such 
as regulation of transcription and gene expression. Second, when using spline-
based models, we are essentially interested in estimating an infinite dimensional 
curve, while in a conventional mixed model the interest is limited to design 
points [71]. In other words, once the fixed and random parameters are estimated 
for the spline-based mixed model, the smooth curve can be realized at any 
desired time point within the design interval. These advantages make mixed 
effects smoothing splines very appealing for analyzing time series gene 
expression data. 
 
2.2. Objectives 
 
The microarray data set was introduced in chapter 1. Briefly, it includes 
transcriptional data of unwounded skin (collected on day 0) and wounded skin 
(collected on days 3, 7, 14, and 21) in db/db and db/+ mice. Figure 6 displays 
properly normalized data along with cubic smoothing splines fit for three 
selected genes (A, B and C). Among the three genes shown in Figure 6, genes A 
and C exhibit different expression profiles in db/db compared to db/+. For gene 
C, however, the temporal trends appear identical in the two groups with the 
exception of a vertical shift caused by differential expression at baseline (day 0). 
In other words, for gene C the effect of time on expression does not depend on 
whether the mice are db/db or db/+, hence the curves are visually parallel. On 
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the contrast, for gene A the effect of time on expression depends in a different 
way upon genotype, leading to visually nonparallel curves. Therefore, our first 
objective is to identify genes such as example A in figure 6, which exhibit distinct 
temporal dynamic in db/db compared to db/+. 
 
Although in time course studies, the interest is generally in gene expression 
dynamic across the entire time frame, occasionally we may be interested in 
pointwise comparison between experimental groups. Functional data analysis 
can also be used to make pointwise comparisons. In fact, the merit of FDA 
approach to analyzing time series data is that by borrowing information from 
adjacent time points, FDA provides a more accurate estimate of true mean at any 
given time point, compared to the average of observations made only at that time 
point. More importantly, FDA allows pointwise comparison at time points 
beyond that of observed data. This flexibility is a unique advantage of FDA 
approach, and holds practical utility as will be shown. 
 
In their original study, Grice et al. reported that on day 7, db/+ wounds were 
67.3% closed, whereas db/db wounds had just returned to their original size 
following an initial increase in size at day 3. By day 14, the next time point after 
day 7, db/+ wounds were completely reepithelialized, whereas db/db wounds 
were only 58.6% closed [27]. Based on these observations, analyzing an 
intermediate time point between day 7 and day 14 would be more pertinent to 
identifying genes that are deregulated between db/db and db/+ at the onset of 
reepithelialization. Therefore, our second objective is to make a pointwise 
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comparison between db/db and db/+ curves in order to identify candidate 
genes that exhibit differential expression at day 10. 
 
 
Figure 6. Example genes from Grice et al. microarray data set, demonstrating either distinct (gene 
A) or similar (genes B and C) temporal patterns in db/db vs. db/+ mice. Red indicates db/db 
and blue indicates db/+ wounds. 
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2.3. Methods 
 
2.3.1. Testing for interaction 
 
Let us consider the dependence of gene expression on time and genotype to be 
additive with a model of the form 
 
                                                      𝑦! = 𝛾!𝑧! + 𝑓 𝑡! + 𝜀!                                             (2.1) 
 
where 𝑦!  is expression of a given gene, 𝑧!  is a binary categorical predictor 
indicating genotype, 𝑡! is time, and 𝜀! is random error with mean equal to zero. 
The 𝛾!𝑧! term represents the vertical shift between db/db and db/+ curves. A 
more general model would be 
 
                                                           𝑦! = 𝑓!! 𝑡! + 𝜀!                                                  (2.2) 𝑧! =     1  𝑖𝑓   𝑡! ,𝑦!   𝑏𝑒𝑙𝑜𝑛𝑔𝑠  𝑡𝑜  𝑑𝑏/𝑑𝑏2  𝑖𝑓   𝑡! ,𝑦!   𝑏𝑒𝑙𝑜𝑛𝑔𝑠  𝑡𝑜  𝑑𝑏/+  
 
where 𝑓! and 𝑓! can be any two smooth curves. It is clear that (2.2) allows for the 
possibility that time and genotype interact with one another, which means that 
the effect of time on gene expression can depend in a completely general way 
upon genotype. We can represent (2.1) using penalized splines introduced in 
previous chapter. A linear penalized spline parameterization of (2.1) would be 
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                                                                                      𝑦! = 𝛽! + 𝛽!𝑡! + 𝑢!(𝑡! − 𝜉!)!!!!! + 𝛾!𝑧! + 𝜀!                                                     (2.3) 
 
Similarly, defining the indicator of the 𝑙!! genotype as  
 𝑧!" = 1        𝑖𝑓  𝑧! = 𝑙        0        𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 
 
for (2.2) we will have 
 
𝑦! = 𝛽! + 𝛽!𝑡! + 𝑢!(𝑡! − 𝜉!)!!!!!   
                                                                                                                      + 𝑧!" 𝛾!! + 𝛾!!𝑡! + 𝜐!" 𝑡! − 𝜉! !!!!! +!!!! 𝜀!                 (2.4) 
 
where a mixed model representation can be obtained by taking 𝑢! i.i.d. 𝑁(0,𝜎!!) 
and 𝜈!" i.i.d. 𝑁(0,𝜎!!). Here we used linear splines for simplicity; the extension to 
cubic splines is straightforward. 
 
Model (2.4) is over-parameterized, i.e. one can add a constant to 𝛽! and subtract 
the same constant from each 𝛾!! without changing the expectation of 𝑦!. In order 
for fixed parameters to be uniquely defined, some constraints are needed on 𝛾!! 
and 𝛾!!. Similar to constraints applied in certain non-full rank ANOVA models, 
we can set 
	  	  
43	  
either    𝛾!" = 𝛾!" = 0    or    𝛾!" + 𝛾!" = 0𝛾!! + 𝛾!" = 0 
 
Adopting either one of above constraints will not change the model fit, however 
the interpretation of parameters will be different. Choosing the first constraint 
will ensure that 
 
                                                                                                              𝛽! + 𝛽!𝑡! + 𝑢! 𝑡! − 𝜉! !!!!!                                                                                           (2.5) 
 
represents the fitted curve for 𝑙 = 2 (db/+ genotype), while 
 
                                                                                                            𝛾!! + 𝛾!!𝑡! + 𝜐!" 𝑡! − 𝜉! !!!!!                                                                                       (2.6) 
 
represents the difference between db/db and db/+ when 𝑙 = 1 and will be zero 
when 𝑙 = 2. If we adopt the second constraint, then (2.5) will represent the 
average curve for both genotypes, and (2.6) will be the deviation for the 𝑙!! 
genotype from the average curve. 
 
Once the models are fit and the fixed and random parameters are obtained using 
the mixed model framework, we can test the significance of the interaction 
between time and genotype by comparing the interaction model (2.4) to additive 
model (2.3). More precisely, we have 
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𝐻!:    𝛾!" =   𝛾!" = 𝛾!! = 𝛾!"    𝑎𝑛𝑑  𝜎!! = 0   𝐻!:  𝛾!" ≠ 0  𝑜𝑟  𝛾!" ≠ 0  𝑜𝑟  𝛾!! ≠ 0  𝑜𝑟  𝛾!" ≠ 0  𝑜𝑟  𝜎!! > 0 
 
Since we fit models using maximum likelihood, the likelihood ratio statistic 
would be a reasonable approach to hypothesis testing. Similar to maximum 
likelihood, likelihood ratio statistic is based on likelihood function. If ℒ(θ; y) 
represents the likelihood of the parameter vector θ based on the data in y, the 
likelihood ratio statistic for testing a null (restricted) model against an alternative 
(unrestricted) model is defined as 
 
                                                                                                                                𝐿𝑅 𝑦 =   ℒ(𝜃!;𝑦)ℒ(𝜃;𝑦)                                                                                                             (2.7) 
 
where 𝜃! and 𝜃 are the maximum likelihood estimates of 𝜃 under the null and 
alternative models, respectively. The likelihood ratio statistic can be viewed as a 
measure of the goodness-of-fit when comparing two nested models. Simply put, 
it compares how likely it is to observe the data at hand under one model than the 
other. In practice, it is more common to work with log-likelihoods 
                                                               −2 log 𝐿𝑅 𝑦 =   −2 log ℒ 𝜃!;𝑦 − log ℒ 𝜃;𝑦                                     (2.8) 
 
where the right-hand side of this equation is commonly referred to as deviance. 
According to Wilk’s theorem, as the sample size approaches infinity, the test 
statistic −2 log 𝐿𝑅 𝑦  will be asymptotically chi-squared distributed with 𝜈 
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degrees of freedom, where 𝜈  is the number of independent parameters in 
alternative model minus the number of independent parameters in null model 
[56]. However, the Wilk’s theorem assumes that the parameter of interest is not 
on the boundary of its parameter space. Since the parameter space for 𝜎!! is [0,∞), this assumption is violated when testing if 𝜎!! = 0. While some asymptotic 
approximations of the test statistic −2 log 𝐿𝑅 𝑦  have been proposed (e.g. 
mixture of chi-squared distributions by [72]), such asymptotic approximations 
assume 1) independence of the y vector under all values of the parameters, and 
2) that the number of independent observations approaches infinity. These 
approximations do not hold in general, and have been shown to be very poor 
when applied to penalized splines [56]. We will therefore determine the critical 
values of the likelihood ratio tests using Monte Carlo simulations as suggested 
by Ruppert, Wand, and Carroll [56]. The procedure is as follows: 
 
First, the fixed effects and variance component parameters are estimated under 
the null. Second, a large number of independent data sets are simulated under 
the null model, with fixed effects and variance component parameters set equal 
to their estimated values under the null hypothesis and covariates equal to their 
observed values. Third, the likelihood ratio statistic is calculated for each 
simulated data set. Finally, an empirical p-value is obtained as the proportion of 
simulated values greater than or equal to the observed value at real data. To 
avoid zero p-values when estimating the tail probability of the likelihood ratio 
statistic, empirical p-values will be calculated as recommended by Phipson and 
Smyth [73]: 
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                                                                                                                                𝑃!"#$%$&'( =    𝑏 + 1𝐵 + 1                                                                                                         (2.9) 
 
where b is the number of simulated likelihood ratio statistics greater than or 
equal to the observed value of likelihood ratio statistics at real data, and B is total 
number of Monte Carlo simulations. 
 
2.3.2. Exploratory analysis of differentially varying genes 
 
Let us consider the dependence of gene expression on time in either db/db or 
db/+ genotypes to be described by the smooth curve 𝑓 
                                                                                                                                       𝑦! = 𝑓 𝑡! +   𝜀!                                                                                                               (2.10) 
 
where 𝑦! is expression of a given gene at time 𝑡!, and 𝜀! = 𝑁(0,𝜎!!) are random 
errors. For the simple linear regression model  𝑦 = 𝑋𝛽 + 𝜀, the least-square fit to 
the data would be 𝑦 = 𝐻𝑦, where 𝐻 = 𝑋(𝑋!𝑋)!!𝑋! is the hat matrix. Analogous 
to this notion, it can be shown that for a fixed smoothing parameter 𝜆, the 
estimate of penalized spline parameterization of 𝑓 in (2.10) at a general value of 
the predictor variable 𝑡 can be computed by 
                                                                                                                                                   𝑦 = 𝑆!𝑦                                                                                                                            (2.11) 
 
where  𝑆! = 𝑋(𝑋!𝑋 + 𝜆!!𝐷)!!𝑋! is called the smoother matrix, 𝑝 is the degree of 
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splines (e.g. 𝑝 = 1  for linear splines or 𝑝 = 3   for cubic splines), 𝐷 = 𝑑𝑖𝑎𝑔(0!!!, 1!) with 𝐾 indicating the number of knots, and 𝑋 corresponds to 
basis functions as described  in chapter 1. Therefore, once the smoothing 
parameter 𝜆 is obtained for a given gene, the smooth curve representing gene 
expression dynamic can be realized at a finite grid of size 𝑚, 𝑡∗ = {𝑡!∗, 𝑡!∗, . . . , 𝑡!∗ }, 
where 𝑡!∗  represents 𝑚!! desired point in time. These estimates can then be used 
for follow-up exploratory analysis. 
 
For instance, we use the finite realization of smooth curves to obtain their 
dynamic range. We define functional range as the absolute difference between 
the maximum and minimum estimate of the curve (Figure 7). By setting a cutoff 
value, e.g. functional range ≥ (𝑙𝑜𝑔!! = 1), we can identify genes that are more 
stable over time. In another application, we use the finite realization of smooth 
curves to perform clustering on the expression profiles of candidate genes in the 
db/db genotype. More specifically, we use the Euclidean distance between 
standardized realization of smooth curves as similarity metric in Ward’s 
agglomerative hierarchical clustering procedure. 
 
While the choice of grid size is arbitrary, it needs to be sufficiently large to give 
an accurate representation of the curve. We found m=100 to give satisfactory 
results in this study. Also, predictions at time points beyond design interval are 
attainable but dubious. Therefore, throughout this work when discretizing gene 
expression curves on a grid, we limit the grid span to design interval [0,21] and 
distribute m=100 time points equally in this interval. 
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Figure 7. Functional range defined as the absolute difference between the maximum and 
minimum estimate of a smooth curve. 
 
2.3.3. Testing for pointwise difference 
 
The linear penalized spline parameterization of (2.10) yields 
 
                                                                                          𝑦! = 𝛽! + 𝛽!𝑡! + 𝑢! 𝑡! − 𝜉! !!!!! + 𝜀!                                                                     (2.12) 
 
which as mentioned in previous chapter can be written as  
 
                                                                                  𝑦 = 𝑋𝛽 + 𝑍𝑢 + 𝜀, 𝐶𝑜𝑣 𝑢𝜀 = 𝜎!!𝐼0 0𝜎!!𝐼                                                         (2.13) 
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where  𝑋 = [1    𝑡!]!!!!!  and  𝑍 = [ !!!!! !!!!!! ]!!!!!. 
 
If we let 𝑋! = [1  𝑡] and 𝑍! = [ !!!! !!!!!! ], and define 𝛽 and 𝑢 as the BLUPs of 𝛽 and 𝑢, 
then the BLUP of 𝑓 𝑡 ≡ 𝑋!𝛽 + 𝑍!𝑢 would be 
                                                                                                                                   𝑓(𝑡) ≡ 𝑋!𝛽 + 𝑍!𝑢                                                                                                        (2.14) 
 
In (2.13), randomness of 𝑢 models curvature of the smooth curve 𝑓, whereas 
randomness of 𝜀 models variability about the curve. Based on this argument, the 
variance of 𝑓 can be calculated with respect to the conditional distribution 𝑦|𝑢 
 
𝑣𝑎𝑟 𝑓 𝑡 𝑢 = 𝑋!  𝑍!   𝐶𝑜𝑣 𝛽𝑢 𝑢 [𝑋!  𝑍!]! 
                                                                                                                                =   𝑊!  𝐶𝑜𝑣 𝛽𝑢 𝑢 𝑊!!                                                                                   (2.15) 
 
where 𝑊! = 𝑋!  𝑍! . Then, from (1.10) of chapter 1 we have 
 
                                                𝐶𝑜𝑣 𝛽𝑢 𝑢 = 𝜎!!(𝑊!𝑊 + 𝜎!!𝜎!! 𝐷)!!  𝑊!𝑊(𝑊!𝑊 + 𝜎!!𝜎!! 𝐷)!!                      (2.16) 
 
which leads to 
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                          𝑠𝑡.𝑑𝑒𝑣 𝑓 𝑡 𝑢 = 𝜎!    𝑊! 𝑊!𝑊 + !!!!!!𝐷 !!𝑊!𝑊(𝑊!𝑊 + !!!!!!𝐷)𝑊!!               (2.17) 
 
where 𝐷 ≡ 𝑑𝑖𝑎𝑔(0,0, 1,… ,1!  !"#$%). This means that for any point in the design interval 
[0,21] days, not only we can compute the estimate of the fit, but also we can find 
the error of the estimate. In return, this allows us to perform a pointwise 
comparison between db/db and db/+ curves at any point of interest in time, 
using the unequal variances t-test also known as Welch’s t-test [74] 
                                                                                                                                         𝑡 = 𝑢! − 𝑢!𝑠!!𝑛! + 𝑠!!𝑛!                                                                                                                 (2.18) 
 
where 𝑢! and 𝑠!! are the estimated fit and its variance at day 10, and 𝑛! is the 
sample size, in either db/db or db/+ genotypes, respectively. Welch 
demonstrated that (2.18) has t-distribution with 𝜈 degrees of freedom, where 
 
                                                                                                      𝜈 = 𝑠!!𝑛! + 𝑠!!𝑛! !𝑠!!𝑛!! 𝑛! − 1 + 𝑠!!𝑛!! 𝑛! − 1                                                                               (2.19) 
 
Therefore, by comparing the observed 𝑡!"#$! with its associated t-distribution we 
can obtain the significance level of the observed difference between db/db and 
db/+ curves at day 10. 
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2.4. Results 
 
2.4.1. Overall performance of the likelihood ratio procedure for testing the 
interaction between the effects of time and genotype on gene expression 
 
Our first objective was to identify candidate genes with distinct expression 
profile between the two genotypes. As outlined in section 2.2 and figure 6, we 
narrowed down this objective by focusing on genes for which the effect of time 
on expression was dependent on whether the mice were db/db or db/+ (i.e. 
seeking visually nonparallel as opposed to parallel curves). To achieve this goal, 
we applied the likelihood ratio procedure to test if there was a significant 
interaction between the effects of time and genotype on gene expression. Figure 
8 shows the distribution of the likelihood ratio statistic obtained using Monte 
Carlo simulation under the null hypothesis of no interaction, for the three genes 
introduced in figure 6. For gene B where the two curves were visually identical, 
4’936 out of 10’000 likelihood ratio statistics were greater than or equal to the 
observed statistic of 1.48, resulting in a p-value of 0.494. For gene C where the 
db/db and db/+ curves were visually parallel (but not identical), 231 out of 
10’000 simulated likelihood ratio statistics were greater than or equal to the 
observed statistic of 12.3, resulting in a p-value of 0.02. On the contrast, for gene 
A with nonparallel curves, all simulated likelihood ratio statistics were smaller 
than the observed value of 51.1, resulting in the small p-value of 9.9E-5. The 
above procedure was repeated for all 21’304 genes, and the resulting p-values 
were adjusted for multiple testing using the method of Benjamini-Hochberg [75]. 
Using a cutoff adjusted p-value of 0.01, 9’957 out of 21’304 genes were deemed 
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significant. In fact, while gene A of figure 6 was deemed significant, the null 
hypothesis of no interaction between time and genotype was not rejected for 
either gene B or gene C, and as a result they did not make it to the list of 
significant genes. Figures 9 and 10 show the expression profile of top and bottom 
five genes, after all genes were ranked based on their likelihood ratio statistic. As 
expected, the most significant genes at the top of the list showed distinct 
temporal dynamic in db/db compared to db/+ (figure 9), whereas little to no 
difference was observed for genes at the bottom of the list (figure 10). 
  
Figure 8. The null distribution of the likelihood ratio (LR) statistic for genes A, B, and C shown in 
figure 6. For each gene, B=10’000 data sets were simulated under the null model. The LR statistic 
was then calculated for each simulated data set. Red dashed lines indicate the observed value of 
the LR statistic for each gene. For gene A, this value was larger than all simulated values. 
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Figure 9. Top 5 genes demonstrating the strongest interaction between time and genotype. Red 
indicates db/db and blue indicates db/+ wounds. 
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Figure 10. Bottom 5 genes demonstrating little to no interaction between time and genotype. Red 
indicates db/db and blue indicates db/+ wounds. 
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2.4.2. Identifying candidate genes showing significant interaction between time 
and genotype 
 
As demonstrated in figure 9, the estimated curves of significant genes identified 
by the likelihood ratio procedure exhibit different extent of variation over time. 
For instance, the 2nd-ranked gene in figure 9 varies over a wide range of almost 
4 measurement units (corresponding to 16 fold change on base 2 log-scale), 
whereas the 5th ranked gene only varies between 9.4 and 10.6. In seeking 
relevant genes, it is therefore plausible to favor genes with large temporal 
variation over genes with moderate variation. To identify significant genes that 
showed large temporal variation over the course of healing, we defined 
functional range as a measure of temporal stability of each curve and used it to 
filter out significant genes with small temporal variation. Applying a cutoff value 
of 1 (corresponding to 2 fold change on base 2 log-scale), we found 4’925 out of 
21’304 genes to have functional ranges greater than or equal to 1. Taking the 
intersection of the two lists, we arrived at 3’530 genes (hereafter referred to as 
candidate genes) that satisfied both criteria; i.e. showed a significant interaction 
between time and genotype, and at the same time had a functional range greater 
than or equal to 1 (Figure 11). Top 10 candidate genes from the intersection of the 
two lists are summarized in Table 1. 
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Figure 11. The overlap of gene lists. The “interaction” list included 9’957 genes that were 
identified to exhibit an interaction between time and genotype based on likelihood ratio statistic. 
The “functional range” list included 4’925 genes with a functional range greater than or equal to 
1. 9952 genes did not belong to either one of the two lists. 
 
Table 1. Top 10 candidate genes exhibited significant interaction between time and genotype, and 
had functional range greater than or equal to 1. 
Ranks Gene Symbol Description p-value 
1 Otop1 Modulates calcium homeostasis and influx of calcium in response to extracellular ATP 5.84E-20 
2 Paqr9 Steroid hormone receptor 6.66E-19 
3 Ncan 
Neurocan is a chondroitin sulfate proteoglycan thought 
to be involved in the modulation of cell adhesion and 
migration; binds to hyaluronic acid 
1.60E-18 
4 Ptchd4 Could act as a repressor of canonical hedgehog signaling 7.76E-18 
5 Rmnd5a Contributes to ubiquitin-protein transferase activity 1.67E-16 
6 Sft2d2 
May be involved in fusion of retrograde transport 
vesicles derived from an endocytic compartment with the 
Golgi complex 
1.68E-16 
7 Ttc7b 
Component of a complex required to localize 
phosphatidylinositol 4-kinase (PI4K) to the plasma 
membrane 
3.06E-16 
8 Pmepa1 Functions as a negative regulator of TGF-beta signaling 5.37E-16 
9 C730029A08Rik - 8.36E-16 
10 Rab34 Plays a role in the maturation of phagosomes that engulf pathogens 5.84E-20 
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2.4.3. Enrichment analysis of candidate genes showing significant interaction 
between time and genotype 
 
To gain insight into the biological role of candidate genes and their contribution 
to different processes during wound healing, we first split significant genes into 
smaller groups based on similarity of their expression profile (Figure 12). The 
hierarchical clustering dendrogram revealed that candidate genes could be 
broadly categorized into three clusters. The first cluster (figure 12, top stripe) 
included 1681 genes demonstrating an early spike between 3-7 days post-
wounding, which gradually returned to baseline by day 21. The second cluster 
(figure 12, middle stripe) included 934 genes that showed a gradual increase over 
the course of healing, reaching their peak at day 14, and maintaining it until day 
21. The final and third cluster (figure 12, bottom stripe) included 915 genes with 
a sharp decrease right after wounding, reaching their minimum at day 3 and 
slowly increasing until day 21 without ever returning to baseline. 
 
Having identified the main trends of expression among candidate genes, we next 
performed enrichment analysis on each cluster using the controlled vocabulary 
of genes and their attributes provided by the Gene Ontology (GO) consortium 
[76, 77]. Using hypergeometric test to assess enrichment of a subset of GO terms 
associated with biological processes (BP subset) among the identified candidate 
genes, overrepresentation p-value was computed for each GO term and further 
adjusted for multiple testing using the method of Benjamini-Hochberg. Figure 13 
summarizes top 20 GO terms for each cluster surviving a cutoff adjusted p-value 
of 0.01, and ranked based on overrepresentation p-values. 
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Figure 12. Hierarchical clustering revealing three major patterns among candidate genes. Top, 
middle, and bottom stripes included 1681, 934, and 915 genes, respectively. 
 
2.4.4. Analysis of candidate genes differentially expressed at the onset of 
reepithelialization 
 
The formation of granulation tissue, also known as reepithelialization, is the 
hallmark of successful wound repair and regeneration [78]. We next set out to 
identify a subset of candidate genes (identified above) that were also 
differentially expressed on day 10 at the onset of reepithelialization. Performing 
a pointwise comparison of the db/db and db/+ curves at day 10, we found 6’520 
out of 21’304 genes to be differentially expressed at day 10. Figures 14 and 15 
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show top and bottom five genes, after all genes were ranked based on the 
absolute value of the pointwise t-statistic computed at day 10. As expected, 
unlike genes ranked at the bottom of the list (figure 15), significant genes at the 
top of the list showed large difference between db/db and db/+ wounds (figure 
14). Taking the intersection of differentially expressed genes at day 10 with the 
previously identified candidate genes, we obtained 1’762 genes that not only 
showed distinct expression profile between the two genotypes, but also were 
differentially expressed at the onset of reepithelialization (Figure 16). Top 10 
candidate genes showing the most significant differential expression at day 10 
are summarized in Table 2.	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Figure 13. Overrepresentation analysis of Gene Ontology (GO) terms among the (A) top, (B) 
middle, and (C) bottom cluster of candidate genes as identified in figure 11. Significant GO terms 
were identified using a cutoff adjusted p-value of 0.01, and further ranked based on the 
significance of the overrepresentation p-value. 
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Figure 14. Top 5 genes demonstrating largest differential expression between db/db and db/+ at 
day 10. Differential expression was assessed using Welch’s t-test based on the estimated fit and 
variance of the fit at day 10 for each curve. Red indicates db/db and blue indicates db/+ wounds. 
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Figure 15. Bottom 5 genes demonstrating smallest differential expression between db/db and 
db/+ wounds at day 10. Differential expression was assessed using Welch’s t-test based on the 
estimated fit and its variance at day 10. Red indicates db/db and blue indicates db/+ wounds. 
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2.4.5. Analysis of selected genes associated with inflammatory response  
 
The phenotype of macrophages is influenced by the wound microenvironment 
and evolves during normal wound healing from a pro-inflammatory (M1) profile 
in early stages, to a pro-healing (M2) phenotype in later stages. This M1-to-M2 
transition is reportedly distorted in diabetic wounds. To verify this claim at the 
transcriptome level, we next compared the expression of selected genes 
associated with M1-M2 activation states between db/db and db/+ wounds. 
Among selected M1 genes (Ccr7, Il1b, Il6, Nos2, Ptgs2, and Tnfa), Ccr7, Il6, and 
Tnfa exhibited interaction between time and genotype, but only Tnfa was 
differentially expressed at day 10 (Figure 17). For the M2 genes (Arg1, Myc, 
Mrc1, Fizz1, Ym1, and Tgm2), except for Myc all exhibited interaction between 
time and genotype and at the same time were differentially expressed at day 10 
(Figure 18). 
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Figure 16. Venn diagram demonstrating the overlap of the three lists. In addition to “interaction” 
and “functional range” lists described in figure 11, the third list included 6520 genes differentially 
expressed at day 10. 8198 genes did not belong to either one of the three lists. 
	  
Table 2. Top 10 candidate genes meeting all three criteria; exhibited significant interaction 
between time and genotype, had functional range greater than or equal to 1, and were 
differentially expressed at day 10. 
Ranks Gene Symbol Description p-value 
1 Hamp2 
Encodes a peptide hormone that functions in the regulation of 
systemic iron metabolism; also controls recycling of iron by 
macrophages 
6.72E-21 
2 Saa1 Binds heparin and has chemoattractant activity 4.09E-20 
3 Atp6v0a1 
Mediates acidification of eukaryotic intracellular organelles 
necessary for intracellular processes such as protein sorting and 
receptor-mediated endocytosis 
1.23E-19 
4 Slc26a4 Sodium-independent transporter of chloride and iodide 1.36E-18 
5 Saa2 Binds heparin and has chemoattractant activity 9.55E-19 
6 Mab21l3 - 3.97E-18 
7 U90926 Putative TNF-resistance related protein 3.70E-16 
8 Defb3 Exhibits antimicrobial activity 2.37E-16 
9 Ldah Serine lipid hydrolase associated with lipid droplets. Highly expressed in macrophage-rich areas in atherosclerotic lesions 2.26E-18 
10 Fcer1a High affinity receptor expressed in most cells, responsible for initiating allergic response 6.72E-21 
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Figure 17. Expression of selected genes associated with M1 macrophage activation. Red indicates 
db/db and blue indicates db/+ wounds. 
 
 
 
Figure 18. Expression of selected genes associated with M2 macrophage activation. Red indicates 
db/db and blue indicates db/+ wounds. 
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Matrix metalloproteinases (MMPs) are a family of extracellular or membrane-
bound proteinases that by acting on a variety of chemokines and cytokines, 
among other proteins, regulate the recruitment of immune cells and their 
activation during wound healing [79, 80]. Moreover, certain MMPs and 
endogenous tissue inhibitors of metalloproteinases (TIMPs) regulating the 
functionality of MMPs, have been proposed as biomarkers in wound healing. For 
instance, increased MMP9 [81] or the ratio of MMP-1 to TIMP-1 [82] has been 
suggested to predict wound healing in diabetic foot ulcers. In agreement with 
these findings, more recently a combination therapy releasing MMP8 while 
inhibiting MMP9 was shown to enhance healing in diabetic mice [83]. To further 
assess temporal variation of MMPs and TIMPs over the course of healing and 
their potential contribution to the resolution of the inflammatory phase, we 
explored the expression profile of 19 out of 24 members of the MMP family along 
with all 4 members of the TIMP family that were present in our data set. We 
found Mmp1a, Mmp1b, Mmp3, Mmp9, and Mmp23 showing significant 
interaction between time and genotype as well as differential expression at day 
10, whereas Mmp2 and Mmp14 only showed interaction, and Mmp19 was only 
differentially expressed at day 10 (Figure 19). As for the TIMPs, both Timp3 and 
Timp4 exhibited significant interaction between time and genotype and were 
differentially expressed at day 10, whereas Timp2 only exhibited interaction 
between time and genotype (Figure 20) 
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(MMPs) over the course of healing. Red indicates 
db/db and blue indicates db/+ wounds. 
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Figure 20. Expression of tissue inhibitor of metalloproteinases (TIMPs) over the course of healing. 
Red indicates db/db and blue indicates db/+ wounds. 
 
2.5 Discussion 
 
Diabetes is a complex disease with systemic effect on cellular metabolism and 
homeostasis. Accumulating evidence suggest an association between diabetes 
and systemic inflammation [84, 85]. Baseline differences in the transcriptome of 
diabetic skin compared to healthy skin have been reported in murine models of 
diabetes as well as in humans [86-88]. As a result, differences observed between 
the expression profiles of db/db wounds compared to db/+ can be attributed to 
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during wound healing, it was therefore essential to focus on temporal dynamic 
of gene expression rather than the expression values per se. In statistical 
modeling, the latter was characterized by allowing for interaction between time 
and genotype in the model, which in return was tested using the likelihood ratio 
procedure. Analogous to likelihood ratio, the significance of the interaction 
between time and genotype could have been tested using an F-like statistic based 
on the residual sum of squares. Another approach could have been to work with 
the first derivative of expression curves, as the first derivative will capture 
temporal dynamic irrespective of baseline expression. While it was not the 
objective of this work to compare alternative methods available for differential 
variation analysis, a future direction may involve comparison of methods in 
terms of their sensitivity and specificity in detecting differential variation. 
Regardless of the choice of statistic, use of exact tests either via permutation of 
samples or Monte Carlo simulations is generally preferred over asymptotic 
methods, for they make no restricting assumption about the distribution of the 
test statistic. A major downside of exact tests, however, is that they are 
computationally intensive. For example, the complete analysis of all 21’304 genes 
with 10’000 null simulations per gene took over a week on a high performance 
cluster computing platform. In our experience, the bottleneck was in the mixed 
model estimation of smoothing parameter. Therefore, another direction for 
future work may involve improvement of existing algorithms to allow for fast 
implementation of proposed methods in routine practice. 
 
Using the likelihood ratio procedure, 9’957 genes were deemed to have exhibited 
significant interaction between time and genotype. While this number may seem 
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large at first, it in fact recapitulates differential variation over the entire interval 
of [0,21] days. In other words, considering the smoothness of expression curves, 
significant differential variation in any subinterval of [0,21] will inevitably lead to 
overall significance in [0,21]. In the classic approach to differential expression 
analysis, we would have had to perform 10 pairwise comparisons (day 3 vs. day 
0, day 7 vs. day 0, day 7 vs. day 3, and so on and so forth) to obtain a similar 
comprehensive result. Aside from having inflated multiple testing error rates, it 
is clear that this approach quickly becomes impractical as the number of time 
points increases; needless to say that it would completely fail for an unbalanced 
design. Furthermore, the fact that certain observations were made at specific time 
points (e.g. at 3, 7, 14, and 21 days post-wounding) does not necessarily imply 
that the experimenters were any less interested in other points in time. In fact, 
the sampling frequency in time course studies is often dictated by practical 
limitations. Hence, a functional approach is more plausible as it takes the entire 
range of measurements into consideration at once. 
 
A large number of candidate genes, nevertheless, makes interpretation of results 
challenging. A common remedy is to opt for large biological effects. To reduce 
the number of candidate genes, we chose to filter out temporally stable genes 
using functional range defined as the absolute difference between the maximum 
and minimum estimates of the curve. In fact, application of functional range in 
this manner is similar in spirit to fold change-based filtering of significant genes 
in static differential expression analysis. Taking the intersection of genes 
showing strong interaction between time and genotype with those possessing a 
	  	  
71	  
sufficiently large functional range, several candidate genes including Otop1, 
Paqr9, Ncan, and Rab34 were identified. 
 
Otopetrin 1 (Otop1) encodes a transmembrane protein that functions as a major 
regulator of intracellular calcium [89, 90]. Calcium plays an indispensible role in 
skin homeostasis and repair. Accumulating evidence suggest the capacity of 
calcium to modulate keratinocyte proliferation, migration, and differentiation. In 
fact, increasing calcium has been shown to induce terminal differentiation and 
loss of mobility in keratinocytes in vitro [91]. Moreover, rapid calcium influx was 
recently identified as one of the earliest signals produced at the wound site 
triggering the cascade of events leading to healing [92]. It was further speculated 
that this calcium influx might trigger hydrogen peroxide production, a major 
driving force for recruitment of immune cells to the wound bed [93]. In parallel, 
Otop1 is also induced during obesity to counteract obesity-associated low-grade 
inflammation via an adaptive mechanism that is believed to help maintain the 
metabolic homeostasis during chronic inflammation. More specifically, it has 
been shown that Otop1 physically interacts with Stat1 to attenuate IFN-gamma 
signaling [89]. Collectively, these findings suggest that Otop1 upregulation may 
attenuate early inflammatory response necessary to kick-start the cascade of 
events leading to healing, and further render epidermal keratinocytes terminally 
differentiated and incapable of migration and proliferation in the db/db skin. 
While our finding confirms upregulation of Otop1 in db/db skin, further studies 
are required to understand the precise contribution of Otop1 to impaired healing 
in diabetic skin. 
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Paqr9, another candidate gene identified in our analysis, is a member of the 
family of hormone receptors mainly expressed on fibroblasts and keratinocytes, 
which bind to steroids such as progesterone and adiponectin. Progesterone plays 
an important role in the epithelial–mesenchymal transition (EMT), which allows 
keratinocytes at the edge of the wound to migrate into the wound bed during 
reepithelialization [94, 95]. Progesterone is also known to induce an M1-like 
phenotype in macrophages, in part due to inhibition of TGF-b signaling, a potent 
immunosuppressant pathway implicated in scarless healing [96]. Similarly, in 
vitro studies have suggested that adiponectin enhances the proliferation and 
migration of keratinocytes via activating the ERK signaling pathway [97]. In 
agreement with these findings, adiponectin-deficient mice suffered from delayed 
healing compared to controls. Interestingly, the impaired healing in adiponectin-
deficient and db/db mice was ameliorated after topical application of 
adiponectin, pointing to the therapeutic potential of ERK signaling pathway in 
management of diabetic wounds [97]. 
 
Other candidate genes, although less studied in the context of wound healing, 
also seemed intriguing. For instance, Neurocan (Ncan) is a chondroitin sulfate 
proteoglycan that mediates reversible binding of cells to hyaluronic acid (HA), 
providing cues for cell orientation and motility [98, 99]. It is known that HA 
concentration increases at the onset of reepithelialization, providing a matrix that 
is more penetrable by cells, and decreases at later stages of wound healing when 
less cellular trafficking is required [100, 101]. The contribution of Neurocan to 
impaired diabetic wound healing, however, has not been documented. Another 
candidate gene, Rab34, is a member of the well-known RAS oncogene family 
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implicated in endocytosis [102]. In light of previous findings suggesting 
dysfunctional macrophage efferocytosis as a major cause of extended 
inflammatory phase in diabetic wounds [22], further investigation into the 
potential contribution of Rab34 to impaired healing in diabetic skin is merited. 
 
GO overrepresentation analysis provided further insight into biological 
processes affected by the identified genes. Of note, different flavors of the 
hypergeometric test exist for overrepresentation analysis. For example, Zhang et 
al. have suggested conditional hypergeometric test that takes into account the 
potential dependence of GO terms [103]. Qureshi and Sacan have proposed a 
weighted hypergeometric test that introduces genewise weights capturing the 
contribution of individual genes into calculations [104]. Our preliminary 
attempts, however, revealed the necessity to take gene expression dynamic into 
consideration when performing overrepresentation analysis. Although this 
observation was expected given the sequence of events taking place during 
different phases of the healing process, it underlines an important challenge in 
knowledge-based interpretation of time series gene expression data. As for 
assessing overrepresentation of GO terms among candidate genes, we first 
clustered candidate genes based on the similarity of their temporal dynamic in 
db/db wounds, and then performed the standard hypergeometric test equivalent 
to a one-sided Fisher’s exact test within each cluster. The emerging picture from 
this analysis included three main classes of biological processes, each 
corresponding to one of the three clusters. For candidate genes demonstrating an 
early peak followed by gradual return to baseline, the overwhelming majority of 
GO terms pointed to cellular proliferation, development, and differentiation. 
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Candidate genes showing an increasing trend over the course of healing revealed 
metabolic processes as the dominant GO terms, whereas those exhibited a sharp 
decrease right after wounding had GO terms related to immune system such as 
cell recruitment, cytokine stimulation, and defense mechanism in common. 
Taken together, by establishing the association between candidate genes and 
various processes known to be implicated in impaired healing, these results 
indicated the physiologic relevance of identified genes. 
 
The formation of granulation tissue, also known as reepithelialization, is the 
hallmark of successful wound repair and regeneration [78][cite]. To investigate 
the cellular and molecular events taking place at the onset of reepithelialization, 
we performed pointwise comparison between db/db and db/+ curves at day 10 
and identified several genes potentially implicated in dysfunctional 
reepithelialization of diabetic wounds. For example, hepcidin antimicrobial 
peptide 2 (Hamp2), the most differentially expressed gene at day 10, acts both as 
an antimicrobial peptide and a regulator of systemic iron metabolism. Hepcidin 
regulates iron metabolism via binding to ferroportin, an iron transporter protein, 
causing its internalization and degradation [105, 106]. In light of its dual 
functionality, it has been proposed that alterations in iron metabolism likely 
occur as part of the host defense to limit the availability of iron to the invading 
microorganisms [107]. Interestingly, it has been shown that iron overloading of 
macrophage in chronic venous ulcers, induces an M1-like phenotype in 
macrophages [108]. In spite of these findings, the relationship between 
dysfunctional iron metabolism and impaired wound healing in diabetic wounds 
is not well understood. Serum amyloid A1 and A2 (Saa1 and Saa2, together 
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SAAs), two other genes identified to be highly differentially expressed at day 10, 
also hold promise as interesting targets despite their contribution to impaired 
healing not being clear. SAAs are acute phase proteins produced mainly by the 
liver in response to tissue injury and inflammation [109]. SAAs levels are also 
increased in chronic inflammatory conditions, including diabetes [109]. It has 
been shown that SAAs increase cytokine production in macrophages [110], and 
promote proliferation of fibroblasts [111]. These findings are in agreement with 
recent studies demonstrating that SAAs fortify M2 macrophage activation 
associated with fibrosis [112]. Importantly, day 10 was not originally included in 
the study as a design point. As mentioned earlier, a unique advantage of 
functional approach to analyzing time series gene expression data is that it 
allows for overall inference in time domain, as well as pointwise inference at any 
point of interest in time. This flexibility is achieved as a result of the smoothing 
procedure, which converts discrete measurements observed over time into a 
functional entity by capturing true signal from the pool of technical and 
biological noise that is inherent in the measurements. 
 
Given the contribution of dysfunctional inflammation to impaired healing and 
the significance of macrophage activation at the center of the inflammatory 
response, we next compared the expression of several genes commonly 
associated with M1-M2 activation states in macrophages between db/db and 
db/+ wounds. We also included MMPs and their inhibitors as modulators of 
inflammation and innate immunity in our analysis. Surprisingly, we did not 
observe major differences in M1-related genes between the two groups. While 
differences were more noticeable for M2 genes, the heterogeneity among the 
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expression pattern of M2 genes was much higher compared to M1 genes, making 
it difficult to draw conclusions based on selected markers. Although 
inconclusive, these findings raise two important points worth considering. First, 
it is well acknowledged that a multitude of markers is required to properly 
characterize different activation states in macrophages. Second, the bulk of our 
understanding of macrophage activation and the derivation of markers 
commonly used to identify each phenotype is based on in vitro studies, in which 
macrophage activation is studied in response to various physical or chemical 
stimuli that may or may not be physiologically relevant. Therefore, the next steps 
would be to extend our analysis beyond a few individual genes by looking into 
transcriptome signatures and signaling pathways underlying these activation 
states, and if possible replace in vitro-derived gene signatures with 
physiologically relevant in vivo-derived signatures. 
 
As for MMPs and TIMPs, contradictory to previous findings, we did not observe 
any differences in the expression profiles of either TIMP1 or MMP8 between the 
two groups. MMP9, however was indeed overexpressed in db/db wounds, 
further corroborating previously reported therapeutic advantage of MMP9 
inhibition [83]. Our results also identified MMP3 and MMP23 with robustly 
distinguishable patterns between the two genotypes, which may provide 
additional targets to rectify the aberrant inflammatory response in diabetic 
wounds. Collectively, these findings provide additional example of the potential 
utility of FDA to address specific biological questions by focusing on expression 
dynamic of individual genes. 
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2.6. Conclusions 
 
In this chapter we analyzed temporal dynamic of transcriptional response during 
impaired wound healing in db/db mice compared to db/+ controls from a 
single-gene perspective. We applied cubic smoothing splines to model gene 
expression dynamic and used its mixed model representation to obtain the 
smoothing parameter. We began our analysis by comparing the expression 
profile of each gene between the two genotypes, using likelihood ratio 
procedure. Having determined candidate genes with distinct expression pattern 
between the two groups, we then used a filtering scheme based on the functional 
range of expression to distinguish genes with large temporal variation from the 
more stable genes. Furthermore, we separated candidate genes based on the 
similarity of their expression profile into three main clusters, and identified main 
biological processes associated with each cluster. Next, we sought to determine 
and characterize a subset of candidate genes that were also differentially 
expressed at day 10, a point of interest in time related to epidermal 
reepithelialization. Finally, we explored expression pattern of several candidate 
genes related to macrophage activation states, as well as MMPs and TIMPs that 
regulate the recruitment and functional roles of the inflammatory cells. 
 
Taken together, our results demonstrated the flexibility of FDA to model 
individual genes and its utility to compare gene expression patterns among 
different conditions. We identified several candidate genes potentially implicated 
in impaired diabetic wound healing. Importantly, these target genes were further 
corroborated by relevant GO terminologies as well as previous findings in the 
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literature highlighting their relevance and potential implication in wound 
healing. Additionally, we also showed the unique advantage of FDA to make 
pointwise comparison at a time point beyond study design, namely the onset of 
reepithelialization during wound healing. 
 
The main limitation of the proposed approach is the minimum number of 
measurements required for fitting cubic smoothing splines. Although useful and 
enlightening to address specific biological questions, challenges associated with 
interpretation of whole-genome transcriptional response from a single-gene 
perspective is another practical limitation. Clearly, more in-depth evaluation of 
biological processes including assessment of the underlying signaling pathways 
is required to complete these finding, which will be explored in great detail in 
the following chapter. 
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CHAPTER 3: FUNCTIONAL GENE SET ANALYSIS 
  
3.1. Introduction 
 
In previous chapter we analyzed transcriptional response during impaired 
cutaneous wound healing in diabetic mice, focusing on one gene at a time. 
Although informative, analyzing individual genes has some limitations. A major 
challenge in genome-wide differential expression analysis is interpretation of 
results. Typical genome-wide differential expression analysis yields dozens 
(often hundreds or thousands) of differentially expressed genes. Indeed, we 
identified 3’530 candidate genes showing differential variation over the course of 
healing in db/db mice compared to db/+ controls. Making sense of such large 
number of genes is not straightforward and has been the focus of ongoing 
research. As demonstrated in chapter 2, overrepresentation analysis is one way 
to begin to interpret a list of candidate genes. However, obtaining such list 
requires genes to first be analyzed individually. When analyzed individually, 
genes with weak-to-moderate signal are unlikely to stand out in a pool of 
technical and biological noise inherent to high throughput molecular data 
obtained from biological systems. Harsh thresholds imposed by multiple testing 
adjustment procedures further exacerbate this effect and may lead to loss of 
potentially useful information. A classic example of this phenomenon was 
reported in the seminal paper by Mootha et al., where a relatively weak (~20%) 
but consistent down-regulation in a group of functionally related genes was 
shown to bear more biological significance than a 20-fold decrease in expression 
of a single gene [113]. Therefore, there is a strong incentive in shifting the 
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perspective from single-gene to multi-gene analysis in genome-wide analysis of 
gene expression. A popular approach that facilitates such transition is to 
incorporate prior biological knowledge into the analysis framework. Prior 
biological knowledge about genes can be summarized in the form of gene sets. 
Here the term “gene set” refers to a set of genes that share some biologically 
relevant characteristic. Examples of gene sets relevant in the context of wound 
healing include but are not limited to genes involved in 
angiogenesis - development of new blood vessels - as an essential process in 
tissue repair, genes coexpressed after exposure to bacterial lipopolysaccharide 
recapitulating immune response to pathogens introduced at the cite of injury, or 
genes sharing similar sequence motifs and thus predisposed to be affected by 
same transcriptional regulatory mechanisms. By focusing on these sets of genes 
for instance, we can begin to investigate the potential implication of aberrant 
angiogenesis, dysfunctional inflammation, or transcriptional regulation in 
impaired diabetic wound healing. 
 
The above examples comprise a small fraction of the variety of hypotheses that 
can be tested using gene sets. In fact, a considerable number of gene sets 
summarizing diverse gene-centric biological information have been curated over 
the years, paving the way in transition from single-gene to multi-gene analysis. 
MSigDB [114], GeneSetDB [115], and EnrichmentMap [116] are examples of 
publicly accessible databases providing a large compendium of annotated gene 
sets, which can be readily incorporated into the analysis framework. 
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Knowledge-based interpretation of genome-wide expression data as outlined 
above is commonly referred to as “gene set analysis” (GSA) and is the focus of 
this chapter. In the first part, we focus on a family of GSA methods known as 
functional class scoring or FCS (the term “functional” in “functional class 
scoring” refers to biological activity and should not be confused with its 
mathematical connotation as in functional data analysis) [117]. Importantly, 
functional class scoring differs from alternative applications of gene-centric 
biological knowledge, namely overrepresentation and topology-based analysis, 
in that 1) it does not rely on a pre-selected gene list, 2) it does not assume gene 
independence, and 3) it does not restrict the analysis to signaling pathways for 
which fully characterized hierarchical gene-gene interactions are known (see 
[117], [118], and  [119] for more details). In the second part, we combine 
overrepresentation analysis (introduced in chapter 2) with gene co-expression 
network analysis as an alternative approach to overcome the limitations of 
analyzing individual genes by utilizing existing gene-centric biological 
knowledge. 
 
From a statistical point of view, FCS approach to GSA can be broadly divided 
into three steps (Figure 21) [117, 118]. First, a gene-level statistic is computed for 
individual members of a gene set. In the second step, gene-level statistics are 
merged into a summary statistic representing gene set as a whole. Finally, the 
significance of the combined statistic is assessed using a theoretical (asymptotic) 
or resampling-based methods. The last two steps can be further divided into two 
categories depending on the formulation of the null hypothesis [120]. In a 
“competitive” test, the null hypothesis is that genes in the set are at most as 
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differentially expressed as genes not in the set. On the other hand, the null 
hypothesis of a “self-contained” test is that genes in the set are not on average 
differentially expressed. Simply put, in a competitive test members of the set are 
vetted against all other genes, whereas in a self-contained test they are analyzed 
irrespective of genes that do not belong to the set. A large number of methods 
have been developed over the past decade testing either a competitive or self-
contained hypothesis (see [121], [118], and [122] for review of existing methods). 
In what follows, we briefly review the main FCS approaches to GSA. 
 
 
Figure 21. Different steps involved in an FCS approach to GSA. 
In one approach, p-values obtained from differential expression analysis are 
regarded as gene-level statistics, which can then be aggregated for a given gene 
set using Fisher’s combined probability test 
 
                                                                                                                          𝑋! =    −2log  (𝑝!)!!!!                                                                                                         (3.1) 
Step-1:
Calculate gene-level statistics
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where 𝑝! is the p-value associated with 𝑖!! member of the set. Fisher showed that 
for independent tests, this statistic follows a chi-squared distribution [123]. The 
independence assumption of Fisher’s combined probability test, however, is not 
valid for most gene sets given that members of a set are biologically associated in 
one way or the other. While several remedies have been proposed to estimate the 
null distribution of Fisher’s combined probability statistic for dependent tests 
(e.g. Brown’s test [124] or Kost’s test [125]), one can use resampling procedures 
that take the dependence of individual tests into account to accurately estimate 
the null distribution. 
 
Similar to Fisher’s combined probability test, Stouffer’s test [126] also combines 
individual p-values but uses the inverse normal cumulative distribution function 
to first convert p-values to z-values, and then defines the Z-statistic as 
 
                                                                                                                                            𝑍 = 𝑧!!!!!𝑚                                                                                                                           (3.2) 
 
where 𝑚 is the size of the set and 𝑧! = 𝜙!! 1− 𝑝! , in which 𝑝! is the p-value 
associated with 𝑖!! member of the set and 𝜙 is the standard normal cumulative 
distribution function. The advantage of Stouffer’s method is that it allows for 
gene-level weights to be incorporated in the calculation of the Z-statistic as in 
 
                                                                                                                                      𝑍 = 𝑤!𝑧!!!!! 𝑤!!!!!!                                                                                                                     (3.3) 
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where 𝑤! represent gene-level weights. 
 
In a similar fashion, Taylor and Tibshirani proposed a tail strength measure, in 
which gene-level p-values were first ranked according to their significance. The 
ranks were then used as weights to calculate the gene set statistic defined as 
 
                                                                                  𝑇𝑆 𝑝!,𝑝!,… ,𝑝! = 1𝑚 1− 𝑝 ! 𝑚 + 1𝑘                                                           (3.4)!!!!  
 
Under the global null hypothesis (i.e. when the null hypothesis holds for all 
members of the set), the 𝑝! are i.i.d. random variables with standard uniform 
distribution. Considering the ordered list of p-values 𝑝 ! ≤ 𝑝 ! ≤ ⋯ ≤ 𝑝 ! , it 
can be shown that the 𝑘!! p-value has a 𝛽 distribution with parameters "𝑘" and "𝑚 − 𝑘 + 1". Therefore, the expected value of the 𝑘!! p-value is 𝑘 (𝑚 + 1). As a 
result, 𝑇𝑆 has expectation zero under the global null hypothesis. In other words, 𝑇𝑆 measures the deviation of each p-value from its expected value, with large 
positive values of 𝑇𝑆 indicating evidence against the global null hypothesis [127]. 
  
In another approach, fold change values or t-statistics between two experimental 
groups are regarded as gene-level statistics. For instance, Kim et al. proposed the 
mean of fold change values of the members of a given set as gene set statistic, 
which was subsequently corrected for the background represented by all gene-
level statistics to obtain the gene set z-score [128] 
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                                                                                                                              𝑍 = 𝑚  ×    𝑆 − 𝜇   𝛿                                                                                                           (3.5) 
 
where S is the mean of fold change values of the members of the set, 𝜇 and 𝛿 are 
the mean and standard deviation of all fold change values including genes that 
are outside the set, and m is the size of the set. 
 
Another example includes the popular limma R-package from Bioconductor, in 
which the mean, median, or sum of gene-level t-statistics have been proposed as 
summary statistic [62]. In keeping with limma’s approach, Efron and Tibshirani 
proposed the max-mean statistic, in which gene-level statistics were first divided 
into two subsets based on the sign of individual t-statistics, i.e. 
 𝑠 𝑡 = 𝑠 ! 𝑡 ,   𝑠 ! 𝑡  
                                                                                                                 𝑠 ! 𝑡 = max  (𝑡, 0)𝑠 ! 𝑡 = −min  (0, 𝑡)                                                                                              (3.6) 
 
The max-mean statistic was then defined as 
                                                                                                                       𝑆!"# = max 𝑠!! , 𝑠!!                                                                                                   (3.7) 
 
where 𝜓 is the set of t-statistics {𝑡!, 𝑡!,… , 𝑡!} corresponding to a given gene set. 
The max-mean statistic is robust in that it will not allow a few large positive or 
negative t-statistics to dominate the summary statistic. Regardless of the choice 
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of summary statistic (mean, median, sum, or max-mean), its significance can be 
assessed using resampling procedures [129]. 
 
In another method, the convolution of probability distributions has been utilized 
to evaluate gene set differential expression [130]. Given that the probability 
distribution of the sum of two or more independent random variables is the 
convolution of their individual distributions, Yaari et al. first assigned a 
differential expression probability distribution function (PDF) to individual 
members of a given set using Welch’s t-distribution. Under the assumption of 
gene independence, gene-level PDFs were then combined into a single PDF, 
where its mean represented average fold change of the members of the set and its 
standard deviation represented fold change dispersion in the set. The standard 
deviation of the unified PDF was finally rescaled to adjust for the potential 
inflation of the variance due to inter-gene correlation. Figure 22 summarizes the 
method of Yaari et al. 
 
Among all FCS approaches to GSA, Gene Set Enrichment Analysis (GSEA) [114] 
is arguably the most widely used method. In GSEA, the first step is to obtain a 
ranked list of genes. Genes may be ranked using a variety of metrics such as 
signal-to-noise ratio, fold change ratio, t-statistic, F-statistic, etc. A weighted 
running-sum statistic is then calculated by walking down the ranked list, 
increasing the test statistic when passing a gene belonging to the set and 
decreasing it otherwise. More precisely, for a list of genes {𝑔!,𝑔!,… ,𝑔!} ordered 
according to the metrics 𝑟 𝑔! = 𝑟! , the fraction of genes in the set S (𝑃!!" ) 
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weighted by their 𝑟! and the fraction of genes not in the set (𝑃!"##), are evaluated 
up to a given rank 𝑖 in the list as 
 
𝑃!!" 𝑆, 𝑖 = 𝑟! !𝑁!!!∈!!!! , 𝑤ℎ𝑒𝑟𝑒  𝑁! = 𝑟! !!!∈!  
                                                                                                                  𝑃!"## 𝑆, 𝑖 = 1𝑁 − 𝑁!!"                                                                                             (3.8)!!∉!!!!  
 
where 𝑁 is the size of the ranked list, and 𝑁!!" is the number of genes in the set. 
The enrichment statistic (ES) is then defined as the maximum deviation from 
zero of 𝑃!!" − 𝑃!"## . As indicated by (3.8), the magnitude of the increment 
depends on the absolute value of the ranking metrics via 𝛾  – a parameter 
describing the weight of the tail in the random walk – analogous to a weighted 
Kolmogorov-Smirnov statistic. In fact, weighting all steps equally (setting 𝛾 
equal to 0) corresponds to the classic Kolmogorov-Smirnov statistic. Finally, the 
significance of the observed ES is assessed using an empirical sample-
permutation scheme, preserving the inter-gene correlation structure of the data. 
 
The essence of GSEA approach is that if genes are ranked according to their 
correlation with class of interest, gene sets associated with phenotypic distinction 
between the two classes are expected to appear toward the top or bottom 
extremes of the ranked list. Similar in spirit to GSEA, the limma R-package from 
Bioconductor also provides the non-parametric Wilcoxon-Mann-Whitney rank-
sum test, or its extension that allows for inter-gene correlation, to test the 
	  	  
88	  
 
Figure 22. Method of Yaari et al. A) Individual gene expression values are compared between the 
two groups to obtain a differential expression PDF for every gene. B) Individual PDFs are 
combined using numerical convolution to obtain a unified PDF for a given gene set, S. Figure 
adapted from [130]. 
 
hypothesis if members of a given set tend to be more highly ranked in terms of a 
test statistic compared to randomly selected genes [131, 132]. 
 
An alternative approach to utilizing gene-centric biological knowledge in 
deciphering transcriptional response is through construction and analysis of 
coexpression networks [133, 134]. Gene coexpression networks are commonly 
used in the literature to contextualize genes of interest and shed light on their 
functional annotation. The working principle of coexpression network analysis is 
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“guilt by association”, which states that genes sharing the same biological 
function or involved in similar transcriptional programs tend to exhibit 
comparable expression profiles [133, 134]. Graphically, in a coexpression network 
nodes or vertices represent genes, and links or edges between pairs of genes 
indicate pairwise coexpression based on a priori defined similarity metric [135]. 
A popular similarity metric is correlation, although alternative metrics have also 
been used to construct coexpression networks [136]. Clustering of genes based on 
pairwise similarity scores yields groups of coexpressed genes commonly referred 
to as coexpression modules. To speculate about the biological role and functional 
annotation of an unknown (or perhaps less studied) gene, one can investigate the 
module that it belongs to. 
 
3.2. Objectives 
 
It is evident from above that the majority of GSA methods have been developed 
with simple case-control studies in mind, and thus are not applicable (at least in 
their original formulation) to time series data. To address this limitation, more 
sophisticated methods have been proposed that aim at extending GSA to 
complex scenarios including time course or longitudinal studies. In reviewing 
the evolution of GSA methods over the past decade or so, two breakthrough 
strategies stand out for extending GSA beyond case-control studies. The first 
strategy involves computation of gene set enrichment at the level of individual 
samples, commonly referred to as “single-sample” GSA. The second strategy is 
based on utilizing the extremely powerful and flexible framework of mixed 
effects models in the context of GSA. 
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The central theme of single-sample GSA is to calculate the degree to which 
members of a given gene set are coordinately up- or down-regulated within 
individual samples. Single-sample GSA (ssGSA) was first introduced by Barbie 
et al., where the popular GSEA approach was extended (see methods section for 
details) to project several gene sets, including NF-kB signaling pathway, across 
individual lung adenocarcinomas to identify co-dependent pathways in KRAS 
mutant tumors [137]. Since then, a number of methods have been proposed that 
achieve the same goal, albeit with subtle differences in the computation of the 
gene set enrichment score (see [138], [139], [140], or [141] for instance). In all 
cases, gene expression data is first transformed to a higher-level space 
representing a more biologically interpretable set of features (i.e. gene sets) for 
individual samples irrespective of the study design. Calculated enrichment 
scores are then used as input to conventional statistical methods for exploratory 
or inferential analysis. 
 
Although in principle this two-step procedure should allow for easy extension of 
GSA to complex scenarios, application of single-sample GSA to time series or 
longitudinal data has been hindered due to inherent challenges of time course 
studies such as small sample size, irregularly spaced time points, missing values, 
and potential correlation of observations. As demonstrated in previous chapter, 
FDA can elegantly circumvent many of these challenges and facilitate both 
exploratory and inferential analysis of time series data. Therefore, our first 
objective is to utilize FDA to extend single-sample GSA to time course studies. 
More specifically, we aim to estimate and compare the enrichment of selected 
gene sets over the course of healing in db/db and db/+ wounds. 
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The mixed modeling framework is extremely rich in that it can handle a diverse 
range of study designs. For this reason, mixed effects models have been utilized 
in the past to investigate temporal variation of gene sets. For instance, Wang et 
al. applied random components to model the mean trajectory of a gene set [142]. 
However, they considered random effect at the array level rather than at the gene 
level, and limited their analysis to monotonic changes of gene set trajectories 
over time. Zhang et al. considered random effect at the gene level, but also 
limited their analysis to linear trends of gene expression over time [143]. Turner 
and colleagues generalized the GSA method of Yaari et al. (Figure 22) for 
repeated measures, confounder adjustment, and continuous covariates by 
utilizing linear mixed models [144]. Of note, Turner et al. fit mixed models at the 
gene level, and then used the model estimates to obtain the mean and standard 
deviation of the gene set fold change expression at each time point for each 
experimental group. Although promising, this generalization still had several 
shortcomings. First, the effect of time on gene expression was assumed to be 
linear. Second, the potential heterogeneity among the members of the set was not 
taken into consideration as the mean and standard deviation of the gene set fold 
change expression was computed independently at each time point. Third, and 
perhaps most importantly, this approach allowed for only one contrast to be 
made at a time; either changes over time or changes between experimental 
groups. 
 
More recently Hejblum and colleagues proposed another method, in which the 
potential heterogeneity among the trends over time for different genes in a given 
gene set was taken into account by fitting the mixed effects model at the gene set 
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level rather than at the gene level [51]. Additionally, the authors allowed for both 
linear and nonlinear trends over time, although the form of dependency on time 
(i.e. linear or cubic) was explicitly specified in the model. While this approach is 
reasonable in modeling the variation of gene expression over time for gene sets 
exhibiting little to moderate heterogeneity, it falls short in modeling gene sets 
with two or more divergent temporal patterns. The reason is that in the mixed 
effects approach to fitting a single model to a given gene set, the underlying 
assumption is that the individual trajectories at the gene level represent a 
Gaussian random process, where the average trend of the gene set is represented 
by the mean trajectory, and individual gene level trajectories are randomly 
distributed around the mean. When this underlying assumption is not met, as it 
is the case in gene sets with divergent temporal patterns, the mixed model 
estimates of random parameters become unreliable. Moreover, the authors 
considered individual gene level trajectories to be independent and used the 
asymptotic null distribution of the likelihood ratio statistic that ignores the inter-
gene correlation in the set. 
 
Clearly, there is currently a gap in the diverse arsenal of GSA methods for a 
statistical approach to compare the temporal variation of a given gene set 
between two experimental groups that 1- accurately captures the temporal 
dynamic of gene level trajectories inside the set, 2- takes into account the inter-
gene correlation among the members of the set, and 3- is robust to potential gene 
set heterogeneity. Intriguingly, two-sample hypothesis testing for functional data 
is a classic problem in the FDA paradigm. Therefore, our second objective is to 
implement a functional test that allows us to compare the underlying functional 
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distribution of selected gene sets over the course of healing in db/db vs. db/+ 
wounds, while meeting all of the above criteria. 
 
Paxillin is a focal adhesion adapter protein that has recently emerged as a 
promising prognostic and therapeutic target in cancer [145-147]. Previous in vitro 
studies have suggested that Paxillin is implicated in angiogenesis and cell 
migration [148-150]. However, the contribution of Paxillin to healing process 
during cutaneous wound healing has not been documented. Therefore, we set 
out to shed light on the biological role of Paxillin during cutaneous wound 
healing using gene coexpression network analysis. A key step in gene 
coexpression network construction is calculation of pairwise similarity scores 
between gene expression profiles. Pearson correlation, the most commonly used 
similarity metric, assumes that observations are independent, thereby ignoring 
the temporal order and potential dependence of time series gene expression data. 
Interestingly, FDA can also be utilized to infer gene coexpression networks from 
time series microarray data. Dubin and Muller introduced the concept of 
dynamic correlation based on the scalar product between two standardized 
smooth curves [151]. Building on this idea, Opgen-Rhein and Strimmer 
successfully applied dynamic correlation to construct gene coexpression 
networks from time series microarray data [152]. As the final objective, we apply 
dynamic correlation to construct the coexpression network of transcriptional 
response during cutaneous wound healing and speculate about the contribution 
of Paxillin to cutaneous wound healing. 
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3.3. Methods 
 
3.3.1. Single-sample GSEA (ssGSEA) 
 
Single-sample GSA was performed by a single-sample extension of GSEA as 
previously described [137]. In summary, pre-processed expression profile for 
each sample was rank-normalized and the gene set enrichment score was 
computed by comparing the empirical cumulative distribution function (ECDF) 
of the members of the set and all genes outside the set. Similar to (3.8), for a list of 
genes {𝑔!,𝑔!,… ,𝑔!} ordered according to their absolute expression value in a 
given sample 𝑘, the fraction of genes in the set S (𝑃!!") weighted by their ranks 𝑟! 
and the fraction of genes not in the set (𝑃!"##), were evaluated up to a given rank 𝑖 in the list as 
 
𝑃!!" 𝑆, 𝑘, 𝑖 = 𝑟! !𝑁!!!∈!!!! , 𝑤ℎ𝑒𝑟𝑒  𝑁! = 𝑟! !!!∈!  
                                                                                                            𝑃!"## 𝑆, 𝑘, 𝑖 = 1𝑁 − 𝑁!!"!!∉!!!!                                                                                           (3.9) 
 
where 𝑁 is the size of the ranked list, and 𝑁!!" is the number of genes in the set. 
We set the weighting parameter  𝛾 equal to 0.25 as suggested by Barbie et al., 
giving moderate weights to the tails. Next, the enrichment statistic (ES) was 
computed for each sample by integration of the difference between the ECDFs 
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                                                                                𝐸𝑆 𝑆, 𝑘 = 𝑃!!" 𝑆, 𝑘, 𝑖 − 𝑃!"## 𝑆, 𝑘, 𝑖                                                             (3.10)!!!!  
 
After enrichment scores were computed for individual samples, they were 
further normalized using the entire set of enrichment scores as 
 
                                                                        𝐸𝑆 𝑆, 𝑘 = 𝐸𝑆(𝑆, 𝑘)!"#!!!,…,!{𝐸𝑆(𝑆, 𝑘)}− !"#!!!,…,! {𝐸𝑆(𝑆, 𝑘)}                                             (3.11) 
 
3.3.2. Two-sample F-like statistic for functional data 
 
Consider two groups of smooth curves, {𝑦!! 𝑡 ,𝑦!" 𝑡 ,… ,𝑦!!!(𝑡)}  and {𝑦!"(𝑡),𝑦!!(𝑡),… ,𝑦!!!(𝑡)}, where each curve has been individually parameterized 
using the cubic smoothing splines approach introduced in chapter 1. The group 
means and the overall mean can then be computed as 
 
                                                                                                                            𝑦! 𝑡 = 1𝑛! 𝑦!! 𝑡!!!!!                                                                                                   (3.12) 
                                                                                                                            𝑦! 𝑡 = 1𝑛! 𝑦!! 𝑡                                                                                                   (3.13)!!!!!  
                                                                                                                  𝑦 𝑡 = 𝑛!𝑦! 𝑡 + 𝑛!𝑦! 𝑡𝑛! + 𝑛!                                                                                         (3.14) 
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Borrowing the idea of functional F-test proposed by Shen and Faraway for 
choosing between two nested functional linear models [153], we define the 
functional F-like statistic as 
 
                                                                                                                                ℱ = 𝑅𝑆𝑆! − 𝑅𝑆𝑆!𝑅𝑆𝑆!                                                                                                         (3.15) 
 
where 
 
                                                𝑅𝑆𝑆! = 𝑦!! 𝑡 − 𝑦! 𝑡 !𝑑𝑡!!!!! + 𝑦!! 𝑡 − 𝑦! 𝑡 !𝑑𝑡                       (3.16)
!!
!!!  
and 
                                                    𝑅𝑆𝑆! = 𝑦!! 𝑡 − 𝑦 𝑡 !𝑑𝑡!!!!! + 𝑦!! 𝑡 − 𝑦 𝑡 !𝑑𝑡                           (3.17)
!!
!!!  
 
If individual 𝑦!! 𝑡  and 𝑦!! 𝑡  curves are discretized over a fine grid of size m 
(e.g. m=100), the integrals in (3.16) and (3.17) can be numerically approximated 
using the trapezoid rule. Intuitively, the F-like test compares the goodness of fit 
of a restricted null model in which an equal mean curve is assumed for the two 
groups, with the alternative model in which each group is represented by a 
distinct mean curve. While Shen and Faraway derived the asymptotic 
distribution of the functional F-statistic under certain conditions, we resort to 
permutation methodology to obtain the distribution of the test statistic under the 
null hypothesis. Under the null hypothesis of equal distributions (not just equal 
means), we randomly permute group labels for individual curves and re-
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compute the test statistic. Repeating this procedure for 1000 times, we obtain the 
empirical p-value as the proportion of test statistics that are greater than or equal 
to the observed test statistic as previously described in chapter 2 (see (2.9) for 
more details). 
 
3.3.3. Gene signatures of classically and alternatively activated macrophages 
 
Raw data was downloaded from Gene Expression Omnibus (GEO) database 
(accession number: GSE69607), and normalized using the RMA algorithm of the 
affy package from Bioconductor [154, 155]. Similar to Grice et al. data set, 
intensity data were converted from probe-level to gene-level using 
mouse4302.db annotation package from Bioconductor [67], and uninformative or 
ambiguous probes for which either no mapping was available or more than one 
mapping was reported were excluded from downstream analysis. In case of 
many-to-one mapping of probe- to gene-ids, the probe with largest coefficient of 
variation across all 8 arrays was retained. Differential expression analysis was 
performed using the limma package from Bioconductor, and p-values were 
adjusted for multiple testing using the Benjamini–Hochberg procedure [62]. 
Using a cutoff adjusted p-value of 0.01, significantly up- and down-regulated 
genes were identified in both M1 and M2 phenotypes compared to M0 controls. 
From the subset of significant genes that were uniquely up- or down-regulated in 
the M1 phenotype, top and bottom 100 genes were selected after genes were 
ranked based on fold change expression. Same analysis was repeated for M2 
phenotype, leading to 4 in vitro-derived gene signatures in total: 
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• M1-up: top 100 genes uniquely up-regulated in M1 phenotype 
• M1-down: bottom 100 genes uniquely down-regulated in M1 phenotype 
• M2-up: top 100 genes uniquely up-regulated in M2 phenotype 
• M2-down: bottom 100 genes uniquely down-regulated in M2 phenotype 
 
Similarly, processed transcriptional profile of F4/80!DICER!/! (hereafter D!/!) 
and F4/80!DICER!/! (hereafter D!/!) TAMs isolated by fluorescent-activated cell 
sorting from mice were downloaded from GEO database (accession number: 
GSE76356). Differential expression analysis was performed using DESeq2 
package from Bioconductor [156]. Using a Benjamini-Hochberg adjusted p-value 
cutoff of 0.05 and a fold change cutoff of 2, significant genes were identified in D!/! TAMs compared to D!/! controls, and subsequently ranked based on their 
log fold change value. Finally, top/bottom 100 significant genes in D!/! TAMs 
were selected as in vivo-derived gene signatures: 
 
• DicerKO-up: top 100 genes up-regulated in D!/! TAMs 
• DicerKO-down: bottom 100 genes down-regulated in D!/! TAMs 
 
3.3.4. Gene coexpression network construction and analysis 
 
Despite being highly positively correlated, temporally stable genes are generally 
not of interest in time course analysis of transcriptional response. Therefore, to 
exclude uninformative similarities from coexpression analysis, we used the 
functional range criterion introduced in chapter 2 to filter out temporally stable 
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genes. Applying a cutoff value of 0.585 (corresponding to 1.5 fold change on base 
2 log-scale), temporally stable genes were filtered out, leaving 7950 genes with 
considerable functional range for network analysis. Pairwise correlation was 
then computed between genes, using two approaches. In the first approach, 
ordinary Pearson correlation was computed on preprocessed gene expression 
data (prior to smoothing). In the second approach, dynamic correlation was 
computed on smooth representation of gene expression curves as previously 
described [151, 152]. In brief, smooth representation of gene expression data was 
obtained using the mixed model formulation of cubic smoothing splines as 
described in chapter 1. Following [151] and [152], the functional inner product 
between two smooth curves 𝑔(𝑡) and ℎ(𝑡) was computed as 
 
                                                                                        < 𝑔 𝑡 , ℎ 𝑡 >  =    1𝐵 − 𝐴 𝑔 𝑡 ℎ(𝑡)𝑑𝑡!!                                                                 (3.18) 
 
where 𝑔(𝑡) and ℎ(𝑡) represent any pair of smooth expression curves, A = day 0, 
and B = day 21. The time average of 𝑔(𝑡)  and ℎ(𝑡)  was then obtained as < 𝑔 𝑡 , 1 > and < ℎ 𝑡 , 1 >, which in return yielded time-centered curves 
 𝑔! 𝑡 = 𝑔 𝑡   −  < 𝑔 𝑡 , 1 >                                                                                                                 ℎ! 𝑡 = ℎ 𝑡   −  < ℎ 𝑡 , 1 >                                                                                        (3.19) 
 
Defining the variances as 
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𝑉𝑎𝑟 𝑔 𝑡 =  < 𝑔! 𝑡 ,𝑔! 𝑡 >                                                                                                         𝑉𝑎𝑟 ℎ 𝑡 =    < ℎ! 𝑡 , ℎ! 𝑡 >                                                                                (3.20) 
 
standardized functions, 𝑔! 𝑡  and ℎ! 𝑡 , were computed as 
 
                                                                  𝑔! 𝑡 = 𝑔! 𝑡𝑉𝑎𝑟(𝑔(𝑡))         𝑎𝑛𝑑        ℎ! 𝑡 = ℎ! 𝑡𝑉𝑎𝑟(ℎ(𝑡))                                           (3.21) 
 
Finally, dynamic correlation between 𝑔 𝑡  and ℎ 𝑡  was computed as 
                                                                                                 𝐶𝑜𝑟 𝑔 𝑡 , ℎ 𝑡 =    < 𝑔! 𝑡 , ℎ! 𝑡 >                                                                    (3.22) 
 
Having computed all pairwise correlations, connection strength (adjacency) 
between genes 𝑖  and 𝑗  was calculated as 𝑎!" = !!!!"! , where 𝑟!"  is the pairwise 
correlation between genes 𝑖  and 𝑗 . Consequently, coexpression networks of 
macrophage transcriptional signature were plotted using the qgraph R package 
[157]. To improve visual assessment, an adjacency cutoff value of 0.9 was applied 
for plotting purposes. Using the same cutoff value, 527 out of 7950 genes were 
found to have high positive dynamic correlation with Paxillin in db/+ wounds. 
Functional annotation of these 527 genes was assessed using the standard 
hypergeometric test and the biological processes subset of the GO terms, as 
previously described [104]. P-values were adjusted for multiple testing using the 
method of Benjamini and Hochberg [75], and significantly overrepresented GO 
terms were determined using a cutoff adjusted p-value of 0.01.  
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3.4. Results 
 
3.4.1 ssGSEA identifies coordinated up- or down-regulation of gene sets in 
simulated data 
 
We first tested the performance of ssGSEA algorithm on a simulated data matrix 
comprised of 100 rows (representing genes) and 10 columns (representing 
samples), where the columns were further split in 2 hypothetical groups (group I 
and group II). The matrix was filled by sampling from a normal distribution with 
mean 0 and standard deviation 1, i.e. ~N 0,1 . We further defined 5 disjoint sets, 
each comprised of 25 rows with various distributions among the 100 rows, and 
amended the simulated data such that set 1 was over-expressed and set 3 was 
under-expressed in group II compared to group I. Figure 23.A demonstrates a 
heatmap of the simulated data matrix along with barcodes depicting the location 
of sets 1-5 among the rows. We then applied the ssGSEA algorithm on this 
simulated data matrix to compute the extent at which each set was enriched in 
individual samples/columns. Figure 23.B shows the distribution of enrichment 
scores as computed by ssGSEA for different sets and different samples in the 
synthetic data matrix. As expected, the enrichment scores were positive when the 
members of the set were encountered on top of the ranked list (set 1), and they 
were negative when the members of the set were accumulated at the end of the 
ranked list (set 3). On the contrary, when the members of the set showed no 
differential expression (set 2), were simultaneously up- and down-regulated (set 
4), or were randomly distributed on the list (set 5), the enrichment scores were 
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Figure 23. Application of single-sample GSA on simulated data. A) Simulated data matrix 
comprised of 100 rows (representing genes), 10 columns divided in 2 groups (representing 
samples), and 5 sets with distinct distribution among the rows. Data was sampled from a normal 
distribution with mean 0 and standard deviation 1, and was further modified such that genes in 
set 1 were expressed at higher levels, and genes in set 3 were expressed at lower levels in group II 
compared to group I. B) Enrichment scores calculated using the method of ssGSEA for simulated 
data matrix shown in panel A.	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comparable among samples. These results demonstrate that single-sample GSEA 
(ssGSEA) allows computation of an enrichment score indicative of the degree of 
coordinated up- or down-regulation of a given gene set for individual samples 
regardless of the study design.  
 
3.4.2. Pathway enrichment in db/db vs. db/+ wounds 
 
We next applied ssGSEA to compute the enrichment of a large compendium of 
pathways (obtained from the REACTOME database [158]) in db/db and db/+ 
wounds. Given the temporal nature of the study, once the enrichment scores 
were computed for individual samples, we used cubic smoothing splines to 
smooth enrichment scores and estimate their temporal pattern over the course of 
healing. Figure 24 shows single-sample enrichment scores along with their 
smoothing splines fit for two example pathways. It can be seen that the 
enrichment patterns are parallel for pathway I. For pathway II, however, the two 
genotypes exhibit distinct enrichment patterns over the course of healing. Similar 
to chapter 2, we were interested in the temporal pattern of gene set enrichment 
scores rather than the enrichment scores per se. This was necessary to exclude 
the effect of differential enrichment at baseline (i.e. day 0). Therefore, we utilized 
the likelihood ratio testing procedure introduced in chapter 2 to identify gene 
sets with distinct enrichment patterns between the two genotypes. Using an 
adjusted p-value cutoff of 0.01, we found 353 significant pathways (out of 674 
pathways in total) with set sizes ranging from 10 to 300. Table 3 summarizes top 
20 pathways with largest likelihood ratio statistics. 
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Figure 24. ssGSEA enrichment scores calculated for two exemplary pathways in db/db (red) and 
db/+ (blue) wounds. Smooth curves represent cubic smoothing splines fit to enrichment scores.  
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Table 3. Top 20 pathways with distinct enrichment patterns in db/db wounds compared to db/+ 
controls. Pathways were obtained from REACTOME database [158]. 
Ranks PATHWAY 
1 MITOCHONDRIAL_PROTEIN_IMPORT 
2 HYALURONAN_METABOLISM 
3 ALPHA_LINOLENIC_ACID_ALA_METABOLISM 
4 CHONDROITIN_SULFATE_BIOSYNTHESIS 
5 NFKB_IS_ACTIVATED_AND_SIGNALS_SURVIVAL 
6 FATTY_ACYL_COA_BIOSYNTHESIS 
7 SYNTHESIS_SECRETION_AND_DEACYLATION_OF_GHRELIN 
8 MEMBRANE_BINDING_AND_TARGETTING_OF_GAG_PROTEINS 
9 TRNA_AMINOACYLATION 
10 HYALURONAN_UPTAKE_AND_DEGRADATION 
11 EGFR_DOWNREGULATION 
12 SIGNALING_BY_FGFR3_MUTANTS 
13 ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS 
14 TRAFFICKING_OF_AMPA_RECEPTORS 
15 SPHINGOLIPID_DE_NOVO_BIOSYNTHESIS 
16 P2Y_RECEPTORS 
17 TCR_SIGNALING 
18 ABCA_TRANSPORTERS_IN_LIPID_HOMEOSTASIS 
19 KERATAN_SULFATE_DEGRADATION 
20 PI_METABOLISM 
 
 
3.4.3. Enrichment of macrophage signatures in db/db vs. db/+ wounds 
 
Based on accumulating evidence including results of chapter 2 and our previous 
work pointing to macrophages as potential prognostic and therapeutic target in 
impaired diabetic wound healing [35, 36], we set out to further investigate the 
enrichment of gene sets associated with macrophage activation states during 
wound healing. We considered both in vitro- and in vivo-derived macrophage 
gene signatures to assess the similarity or potential discrepancy between the two 
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sources. We defined three sets of macrophage-derived transcriptional signatures 
using previously published data. The first and second sets included the typical in 
vitro-derived macrophage transcriptional signatures representing the far 
extremes on a linear M1-M2 spectrum [159]. For each phenotype 100 up-
regulated genes (M1-up and M2-up) and 100 down-regulated genes (M1-down 
and M2-down) were selected as gene signatures. The third set included 
transcriptional signature of Dicer-knockout tumor associated macrophages 
(DicerKO TAMs), which was recently shown to exhibit functional M1 
characteristic in vivo [160]. Similarly, from those genes that were differentially 
expressed in DicerKO TAMs compared to controls, 100 up-regulated genes 
(DicerKO-up) and 100 down-regulated genes (DicerKO-down) were selected as 
gene sets. We then computed the ssGSEA enrichment score for the db/db and 
db/+ wound samples using these gene sets. Surprisingly, we found no difference 
between the enrichment pattern of conventional M1 (stimulated by IFNg and 
LPS) and M2 (stimulated by IL-4) gene signatures in db/+ wounds (Figure 25.A). 
With the exception of M2-up signature, same observation was also made for 
db/db wounds (Figure 25.B). Unlike in vitro-derived signatures, the enrichment 
pattern of DicerKO signatures in db/+ wounds did match the general M1-to-M2 
transition that is widely described in the literature. More interestingly, we 
observed a remarkable inverse correlation between DicerKO-up and DicerKO-
down enrichment patterns in both db/+ and db/db wounds (Figure 25.C-D). 
Furthermore, in agreement with previous in vivo reports, our analysis revealed a 
prolonged enrichment of DicerKO-up signature in db/db wounds compared to 
db/+ (Figure 25.E). 
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Figure 25. Enrichment pattern of macrophage transcriptional signature in A) db/+ and B) db/db 
wounds. ssGSEA enrichment scores were computed for each signature and their temporal 
pattern was estimated by cubic smoothing splines. To emphasize on temporal dynamic of gene 
set enrichment, smooth curves were further standardized prior to plotting. Enrichment patterns 
of DicerKO.up and DicerKO.down signatures were inversely correlated in C) db/+ and D) 
db/db wounds, with E) prolonged enrichment of DicerKO.up signature in db/db wounds. 
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3.4.4. Functional F-statistic to test if two samples of curves have the same 
underlying distribution 
 
So far we have investigated enrichment of a given gene set by comparing the 
coordinated up- or down-regulation of the members of the set to all other genes 
on the array. An alternative approach is to investigate the members of the set 
without reference to other genes, and ask if for a given set the temporal pattern 
of gene-level trajectories are different between the two genotypes. The functional 
F-statistic provides an intuitive and powerful approach to test if two groups of 
curves have the same underlying distribution, while taking both within-group 
and between-group heterogeneity of functions into account. To demonstrate the 
performance of the functional F-test, we first applied it to two sets of curves 
selected from the dendrogram of Figure 12. For the first toy set, we randomly 
chose 70 curves from the top cluster and split them into 2 groups to mimic a 
scenario in which all functions were drawn from one functional distribution. For 
the second toy set, first we randomly chose 35 curves from the top cluster, and 
then chose another 35 curves from the middle cluster, mimicking a scenario in 
which each group of curves was drawn from a different functional distribution. 
The number 35 was selected based on median set size in the REACTOME 
database. Figure 26 illustrates these scenarios along with their corresponding 
observed and null F-statistics. As expected, when the two groups had the same 
underlying functional distribution (toy set I), the observed F-statistic was 
comparable to F-statistics simulated under the null hypothesis. Conversely, 
when the two groups had different underlying functional distributions (toy set 
II), the observed F-statistic surpassed the majority of null statistics. Taken 
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together, these examples demonstrate the utility of the functional F-test in testing 
the equality of underlying functional distributions between two groups of 
functional data. 
 
 
 
 
Figure 26. Application of functional F-test on toy gene sets. A) Toy set 1 was selected such that it 
had the same functional distribution in db/+ (blue) and db/db (red) wounds. B) Toy set 2 was 
selected such that it had different functional distributions in db/+ (blue) vs. db/db (red) wounds. 
Under the null hypothesis of equal distributions, group labels were permuted and the F-statistic 
was recalculated for a 1000 times for toy set I (C) and toy set II (D). Red dashed lines indicate the 
observed F-statistics. 
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3.4.5. Functional F-test identifies gene sets with distinct underlying distributions 
in db/db vs. db/+ wounds 
 
We next sought to compare the temporal dynamic of gene sets in the 
REACTOME database, as well as the in vivo-derived macrophage transcriptional 
signatures in db/db versus db/+ wounds using the functional F-test. Setting the 
Benjamini–Hochberg adjusted p-value cutoff to 0.05, we found 52 gene sets (out 
of 674 in total) with sizes ranging from 10 to 300 in the REACTOME database 
that had significantly different functional distributions in db/db wounds 
compared to db/+. Table 4 summarizes top 20 significant pathways with largest 
F-statistics, and Figure 27 provides visualization of two representative pathways 
from this list. Of note, we did not find the functional distribution of either 
DicerKO.up or DicerKO.down gene signatures to be different between db/db 
and db/+ using the functional F-test. 
 
3.4.6. Gene coexpression network analysis suggests Paxillin is implicated in 
angiogenesis and immune response regulation during wound healing 
 
An alternative application of GSA is functional annotation prediction [117, 118]. 
One approach that utilizes GSA to infer about biological functionality and 
potential implication of unknown or less-studied genes is coexpression network 
analysis [133, 134]. We end this chapter by utilizing this approach to speculate 
about the biological role of Pxn, the gene encoding for the focal adhesion adapter 
protein Paxillin, during cutaneous wound healing. 
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Table 4. Top 20 gene sets in the REACTOME database showing significantly different functional 
distributions in db/db wounds compared to db/+ controls. Gene sets were ranked based on F-
statistic. 
Ranks PATHWAY F-statistic 
1 UNWINDING OF DNA 0.847 
2 DNA STRAND ELONGATION 0.499 
3 POLYMERASE SWITCHING 0.429 
4 LAGGING STRAND SYNTHESIS 0.414 
5 EXTENSION OF TELOMERES 0.404 
6 RESPIRATORY ELECTRON TRANSPORT 0.348 
7 ACTIVATION OF THE PRE REPLICATIVE COMPLEX 0.343 
8 PROCESSIVE SYNTHESIS ON THE LAGGING STRAND 0.315 
9 REPAIR SYNTHESIS FOR GAP FILLING BY DNA POL IN TC NER 0.309 
10 FORMATION OF ATP BY CHEMIOSMOTIC COUPLING 0.304 
11 
RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS BY 
CHEMIOSMOTIC COUPLING AND HEAT PRODUCTION BY 
UNCOUPLING PROTEINS 
0.298 
12 RECRUITMENT OF NUMA TO MITOTIC CENTROSOMES 0.214 
13 G1 S SPECIFIC TRANSCRIPTION 0.207 
14 G2 M CHECKPOINTS 0.186 
15 ACTIVATION OF ATR IN RESPONSE TO REPLICATION STRESS 0.169 
16 CYTOSOLIC TRNA AMINOACYLATION 0.169 
17 TRANSLOCATION OF ZAP 70 TO IMMUNOLOGICAL SYNAPSE 0.165 
18 PD1 SIGNALING 0.158 
19 E2F MEDIATED REGULATION OF DNA REPLICATION 0.153 
20 TRNA AMINOACYLATION 0.142 
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Figure 27. Selected gene sets among the top 20 sets with largest F-statistic. Blue and red indicate 
db/+ and db/db, respectively. 
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The first step in gene coexpression network analysis is to compute pairwise 
similarities between genes. Conventional correlation or Bayesian metrics used for 
quantifying the dependency between expression profiles rely on the i.i.d. 
assumption of observations, and thus are not appropriate for time series 
microarray data. One solution offered by FDA is the concept of dynamic 
correlation [151, 152]. To demonstrate the superiority of dynamic correlation to a 
non-functional approach to computing pairwise correlations, we compared the 
coexpression network of DicerKO-up signature constructed using dynamic            
correlation, with the network constructed using ordinary Pearson correlation in 
db/+ and db/db wounds. As demonstrated in Figure 28, ignoring the temporal 
nature of data using Pearson correlation led to loss of information about 
similarity of expression profiles depicted by a loosely connected network in both 
db/+ and db/db wounds. 
 
Figure 29 provides visualization of the coexpression sub-network surrounding 
Paxillin in the db/+ wounds. We next examined pairwise dynamic correlations 
between Paxillin and all other genes in db/+ wounds, and used a connection 
strength (i.e. adjacency) threshold of 0.9 to identify 527 genes highly coexpressed 
with Paxillin, hereafter referred to as Paxillin module. Interestingly, 
overrepresentation analysis of GO biological processes (BP subset) revealed 
angiogenesis and immune response regulatory processes as top GO terms 
enriched among the members of the Paxillin module (Table 5). These results 
suggest that Paxillin may be implicated in regulating angiogenesis and 
inflammatory response during cutaneous wound healing. 
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Figure 28. Comparison between dynamic and Pearson correlation in gene coexpression network 
construction. Pairwise correlations were computed between all members of the DicerKO-up gene 
set in db/+ and db/db wounds using either dynamic or Pearson correlation. Pairwise 
correlations were converted into adjacencies, and coexpression networks were plotted with the 
qgraph R package using two different layouts (spring and circle) [157]. To improve visualization, 
only adjacencies greater than 0.9 were plotted. 
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Figure 29. Gene coexpression sub-network surrounding Paxillin. To improve visualization, only 
nodes with path length less than or equal to 10 and edges with adjacency greater than or equal to 
0.95 were considered. 
	  
Table 5. Top 10 GO biological processes enriched in the Paxillin coexpression module. 
Rank GO (Biological Processes) p-value 
1 ANGIOGENESIS 3.22E-27 
2 REGULATION_OF_TRANSPORT 2.37E-25 
3 IMMUNE_SYSTEM_PROCESS 6.21E-25 
4 POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 2.61E-24 
5 RESPONSE_TO_EXTERNAL_STIMULUS 9.99E-24 
6 REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 2.37E-22 
7 REGULATION_OF_IMMUNE_SYSTEM_PROCESS 4.67E-22 
8 RESPONSE_TO_ENDOGENOUS_STIMULUS 2.37E-21 
9 POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 9.54E-21 
10 CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE 1.03E-20 
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3.5. Discussion 
 
The goal of GSA is to analyze and interpret gene expression in the context of 
prior knowledge about the relevance and contribution of individual genes to 
various biological processes. As outlined in the beginning of this chapter, the 
overwhelming majority of existing GSA methodologies have been developed 
with simple case-control designs in mind and thus are not applicable (at least 
directly or in their original formulation) to more complex scenarios including 
time course or longitudinal studies. Although not originally developed for time 
series data, single-sample GSA (ssGSA) has the potential to be extended to time 
course studies. In ssGSA, coordinated up- or down-regulation of the members of 
a given set is first quantified to obtain an enrichment score for individual 
samples regardless of group labels or study design. The enrichment scores are 
then employed for hypothesis testing or exploratory analysis using statistical 
methods that are tailored to a given study design. 
 
With several ssGSA methods currently available in the literature [137-141], the 
bottleneck in the application of ssGSA to time course studies is not in the 
computation of the enrichment scores, but instead in downstream inferential 
analysis of the scores. In a time course study, the enrichment scores computed 
for individual samples essentially form a time series, and thus are subjected to 
various challenges associated with analyzing time series data as previously 
discussed. Therefore, in the first part of this chapter we set out to extend ssGSA 
to time course studies by utilizing the FDA framework implemented in previous 
chapter. Of the several existing ssGSA methods, we chose the single-sample 
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extension of GSEA (ssGSEA) as a representative approach that has been 
extensively validated both numerically and experimentally [161, 162]. In line 
with testing the interaction effect of time and genotype on gene expression, we 
were interested in the temporal pattern of enrichment scores and not in the 
enrichment scores per se. This was necessary to exclude differences observed in 
enrichment profiles that were entirely driven by differential enrichment at the 
baseline (i.e. day 0). Consequently, the likelihood ratio procedure introduced in 
previous chapter was applied on the smooth estimates of enrichment scores 
obtained from ssGSEA, to compare the temporal dynamic of enrichment scores 
in db/db wounds versus db/+. Repeating this analysis for all gene sets in the 
REACTOME database, we found several interesting hits related to mitochondrial 
homeostasis, constituents of the extracellular matrix (ECM), NF𝜅𝛽  signaling 
pathway, fatty acids biosynthesis and metabolism, as well as epidermal and 
fibroblast growth factors. 
 
With over 99% of mitochondrial proteome being imported from nucleus, the 
mitochondrial protein import machinery plays an indispensible role in 
mitochondrial homeostasis [163]. Besides being the powerhouse in which cellular 
respiration and energy production occur, mitochondria are also a major source of 
reactive oxygen species (ROS) within most mammalian cells [164-166]. While 
moderate levels of free radicals are beneficial to wound healing, elevated and 
sustained free radicals or ROS has long been associated with impaired healing in 
chronic wounds [167]. In fact, excessive ROS can lead to over-production of pro-
inflammatory cytokines as well as matrix metalloproteinases; both believed to 
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contribute to impaired diabetic wound healing [168]. As a result, targeting 
mitochondrial ROS has recently emerged as a novel therapeutic approach for 
various inflammatory conditions [164]. More recently, in two separate studies 
modulation of mitochondrial ROS was shown to regulate wound healing. Using 
antioxidants to quench mitochondrial ROS in fibroblasts, in one study Janda and 
colleagues showed that ROS levels affect expression of several genes such as 
Cxcl3, Timp1, Col1a1, Acta2, and Angpt1 among others, that are central to the 
wound healing process [165]. In another study, Demyanenko et al. showed that 
application of a mitochondria-targeted antioxidant to dermal wounds 
normalized both inflammatory and regenerative phases of wound healing in 
db/db mice [166]. 
 
Glycosaminoglycans (GAGs) and proteoglycans (PGs), namely hyaluronan and 
chondroitin sulfate, are among the primary constituents of the ECM. As 
discussed in previous chapter, chondroitin sulfate PGs mediate reversible 
binding of cells to hyaluronic acid (HA), providing cues for cell orientation and 
motility. With its remarkable capacity to absorb water, HA is believed to play an 
important role in maintaining wound hydration [98]. Furthermore, HA is an avid 
scavenger of free radicals and tissue degrading enzymes that are detrimental to 
tissue granulation [169]. In keeping with this, it has been reported that HA 
concentration increases at the onset of reepithelialization, providing a matrix that 
is more penetrable by cells, and decreases at later stages of wound healing when 
less cellular trafficking is required [100, 101]. These characteristics have already 
led to various forms of HA-based wound dressings with proven safety and 
efficacy in treatment of diabetic ulcers [170, 171]. 
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The nuclear factor 𝜅𝛽 (NF𝜅𝛽) pathway, another gene set identified by functional 
analysis of ssGSEA enrichment scores, is a hallmark of inflammation triggered 
by TNF-𝛼 and IL1-𝛽, two main pro-inflammatory cytokines over-expressed in 
diabetic wounds [172]. In fact, regulating the inflammatory response via 
modulation of NF𝜅𝛽 signaling has been an active area of research in chronic 
wound healing. For instance, Sirt6 (a nuclear deacetylase) [173] and Substance P 
(a peptide that triggers M2 activation in macrophages) [174] are two compounds 
normally suppressed in diabetic wounds that have been shown to facilitate 
diabetic wound healing by inhibition of the NF𝜅𝛽 activation when reintroduced 
in the wound bed. Identification of several pathways related to fatty acid 
biosynthesis and metabolism provides additional support for the interaction 
between dysfunctional inflammation observed in diabetic wounds and lipid 
metabolism. The crosstalk between lipid metabolism and dysfunctional 
inflammation can be best described via lipid-activated nuclear receptors known 
as peroxisome-proliferator-activated receptors (PPARs) and liver X receptors 
(LXRs). It is well understood that PPARs and LXRs are activated by fatty acids 
and lipid metabolites and regulate the expression of a myriad of inflammatory 
genes [175]. Interestingly, PPAR𝛾 deficiency was recently shown to contribute to 
dysfunctional clearance of apoptotic cells [176]. In line with aberrant M1-to-M2 
transition observed in diabetic wounds, PPAR𝛾 has also been identified as an 
essential mediator of M2 activation in macrophages [177]. Furthermore, direct 
administration of fatty acids or modulation of lipid metabolisms have been 
shown to affect wound healing in vivo. In one example, topical [178] and oral 
[179] administration of linolenic acid were shown to improve skin wound 
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healing via modulation of the immune response [180]. In yet another example, 
SPK1, a key enzyme in sphingolipid metabolism, was shown to improve 
cutaneous wound healing in diabetic rats [181]. In light of these findings, more 
research is required to delineate how cellular metabolism and in return 
dysfunctional inflammation can be rectified at the wound bed. 
 
Epidermal growth factor receptor (EGFR) down-regulation and signaling 
through fibroblast growth factor receptor-3 (FGFR3) were two gene sets related 
to growth factors among the top 20 hits. EGF is a major regulator of proliferation 
and migration of keratinocytes, endothelial cells, and fibroblasts [182]. Indeed, 
EGFR knockout mice show impaired healing compared to wild type controls 
[183]. Moreover, it has been demonstrated that high glucose impairs EGFR 
signaling and results in delayed healing in diabetic corneas [184, 185]. The 
contribution of EGFR signaling to impaired healing in diabetic skin, however, is 
not well documented. FGFR3, one of the 4 receptors of fibroblast growth factors, 
is an active participant in cytokine-mediated regulation of angiogenesis. In 
agreement with previous reports demonstrating down-regulation of FGFR3 in 
db/db wounds [186], our analysis indicated a sharp decrease in FGFR3 signaling 
during the early phase of healing. Interestingly, topical application of FGF has 
been shown previously to improve cutaneous wound healing in db/db mice 
[187]. The temporal pattern of the activity of growth factors or their downstream 
signaling pathways as revealed by FDA, could indeed guide future design of 
growth factor delivery treatments including EGF and FGF. 
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The remaining top 20 pathways identified include the hunger hormone ghrelin, 
purinergic signaling (via P2Y receptors), glutamate signaling (via AMPA 
receptors), T cell receptor signaling, and phosphatidylinositol metabolism, all of 
which hold great promise for further investigation. For instance, ghrelin is a 
circulating peptide that stimulates appetite and regulates energy expenditure in 
the body [188]. Interestingly, ghrelin is also an immunomodulatory molecule. In 
vitro, ghrelin reportedly inhibits the production of pro-inflammatory cytokines 
in peripheral blood mononuclear cells (PBMCs) as well as in T cells [188]. In a 
murine model of burn injury, ghrelin accelerated wound healing via suppression 
of NF𝜅𝛽-mediated inflammatory response [189]. Further experiments are needed 
to assess the exact contribution of ghrelin to impaired diabetic wound healing. 
 
Various inflammatory conditions are associated with free extracellular 
nucleotides, particularly ATP [190]. These nucleotide-signaling molecules 
primarily function through activation of purinergic P2 receptors such as P2Y. 
While a few studies have suggested that P2Y receptors are involved in epithelial 
cell communication and migration (e.g. see [191] and [192]), the contribution of 
extracellular nucleotide signaling and metabolism to impaired diabetic wound 
healing has not been documented. In skin, glutamate receptors or AMPAs are 
predominantly expressed on keratinocytes and thus are expected to be involved 
in epidermal wound healing [193]. While previous studies have demonstrated 
that diabetes affects the levels of glutamate receptors in rat retina [194], we could 
not find any similar reports in the context of cutaneous wound healing.   
 
	  	  
122	  
Epidermal T cells have recently emerged as a novel therapeutic target for 
treatment of chronic wounds. In wounded skin, 𝛾𝛿  T cells respond to 
keratinocyte-specific antigens and contribute to healing by local release of EGF 
and inflammatory cytokines. When 𝛾𝛿  T cells were depleted from the skin, 
wounded but otherwise healthy mice suffer from impaired healing [195]. 𝛾𝛿 T 
cells have also been shown to be required for M2 activation of pulmonary 
macrophages [196], which suggests they may also contribute to the M1-to-M2 
transition of macrophages over the course of healing. More interestingly, while 𝛾𝛿  T cells are activated and secrete EGF in patients with healing wounds, 
patients with chronic nonhealing wounds exhibit dysfunctional 𝛾𝛿 T cells [195]. 
More recently, Liu and colleagues proposed defects in epidermal 𝛾𝛿  T cells 
characterized by reduced production of IL-17 as a major underlying mechanism 
of delayed healing in diabetic mice [197]. 
 
Phosphatidylinositol (PI) metabolism is yet another interesting pathway that 
may serve as a therapeutic and diagnostic target in diabetic wounds. The effect of 
electrical signals on cellular movement and migration has long been appreciated 
in the wound healing community. However, the signaling pathway that directs 
cells to electric cues and regulates electric field-induced wound healing was not 
known until a decade ago. In a fascinating work, Zhao and colleagues identified 
phosphatidylinositol as a major component of the signaling pathway that links 
electrical signals and wound healing [198]. More interestingly, Shen and 
colleagues recently demonstrated that diabetic cornea produce significantly 
weaker electric signals in diabetic mice, and further proposed this observation as 
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an underlying mechanism of impaired healing [199]. In light of these 
observations, identification of PI metabolism as a major pathway with distinct 
enrichment profiles between db/db and db/+ skin merits further investigation 
of its implication in impaired diabetic wound healing. 
 
In addition to REACTOME database, we also tested our combinatorial approach 
(ssGSEA+FDA) on selected macrophage transcriptional signatures. We have 
previously shown that expression of 7 genes associated with M1-M2 activation 
states in macrophages may hold prognostic value in distinguishing healing vs. 
nonhealing diabetic ulcers [35]. Other studies have also explored macrophage-
related gene expression patterns during wound healing in animal models of 
diabetes, as well as in patients [13, 200]. GSA provides a statistically sound 
approach to expand the list of macrophage markers beyond a handful of genes to 
gene signatures that more accurately capture macrophage transcriptional 
programs. Over the past decade, a large number of studies have characterized 
macrophage transcriptional signature in response to various physical and 
biochemical cues (e.g. [201-203]). However, inconsistencies in the cell source, the 
choice of activators, and the collection of markers used to describe activation 
states, had made cross-comparison and collective interpretation of results 
challenging. In 2014, a group of experts in the field of macrophage biology 
proposed a set of nomenclature and experimental guidelines to standardize 
experimental procedures [204]. Following these guidelines, Jablonski et al. 
performed microarray analysis to obtain transcriptional signature of mouse 
macrophages at the extremes of the canonical M1-M2 activation spectrum (see 
[159] for detailed experimental procedure). Of note, Jablonski and colleagues 
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used the same microarray platform (Affymetrix Mouse Genome 430 2.0 Array) as 
in Grice et al. study. As a result, deriving gene signatures from this data set rules 
out the potential effect of cross-platform microarray analysis on our results. 
Nevertheless, a general criticism of in vitro-derived gene signatures is that the 
experimental conditions used to induce macrophage activation are not 
physiologically relevant, and thus may not recapitulate in situ macrophage 
activation. Recently, Baer et al. established a mouse model in which the genetic 
deletion of the microRNA-processing enzyme DICER in tumor associated 
macrophages (TAMs) induced M1-like reprograming of TAMs via IFN-γ/STAT1 
signaling pathway [160]. In addition to extensive functional characterization, the 
authors also characterized the transcriptional landscape of Dicer-knockout TAMs 
using next generation RNA-sequencing technology. Using the transcriptional 
signature of Dicer knockout TAMs as in vivo-derived M1 gene signature and 
comparing it side-by-side with in vitro-derived signatures, we made several 
interesting observations. 
 
In db/+ wounds where the expected temporal pattern of M1- and M2-like 
macrophages is well described in the literature, we did not find any differences 
among the temporal dynamic of enrichment scores for M1up, M1down, M2up, 
and M2down signatures. While the enrichment pattern of M1up signature 
matched the established trafficking of M1-like macrophages in wound bed, 
M2up enrichment pattern clearly contradicted previous in vivo studies showing 
predominance of M2-like macrophages at later stages during healing. 
Furthermore, and quite unexpectedly, up- and down-regulated genes showed 
similar patterns for both M1 and M2 signatures. We found a similar pattern for 
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DicerKO-up gene signature, in harmony with the expected trafficking of M1-like 
macrophages during the course of healing. However, unlike in vitro-derived 
signatures, we observed a remarkable inverse correlation between up- and 
down-regulated genes for in vivo-derived DicerKO signature. More importantly, 
in agreement with previous reports, we found the enrichment of DicerKO-up 
signature to be extended in time in db/db wounds compared to db/+ controls, 
further suggesting a delayed/dysfunctional M1-to-M2 transition in db/db 
wounds. Collectively, these findings cast additional doubt on the physiological 
relevance of in vitro-derived macrophage transcriptional signatures, and 
demonstrate the potential utility of DicerKO TAM signature as a more reliable 
substitute. Future work may include isolation and sequencing of macrophages 
from diabetic wounds, to obtain even better signatures. Regardless of the choice 
of signature, these findings demonstrate the utility of FDA in extending ssGSA 
procedures to time course studies. Another future direction may involve 
benchmarking of different ssGSA procedures in combination with FDA to 
compare their performance in analyzing time series gene expression data. 
 
The ssGSA approach falls under the competitive GSA category, as members of 
the set and genes that are not in the set both contribute to the calculation of the 
enrichment score. An alternative approach is to begin from individual gene-level 
trajectories for a given set, and compare the collective pattern of expression 
profiles between the two genotypes. Unlike ssGSA, in this case genes that are 
outside the set have no influence on our assessment of the temporal pattern of a 
given gene set. As a result, this approach falls under the self-contained family of 
GSA methods. In light of previous attempts at comparing the temporal variation 
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of a given gene set between two experimental groups, we were particularly 
interested in a statistical framework that accurately captures the temporal 
dynamic of gene level trajectories inside the set, takes into account the inter-gene 
correlation among the members of the set, and is robust to potential gene set 
heterogeneity.  
 
Two-sample hypothesis testing of functional data is a classic problem in FDA 
literature. Several methods have been proposed over the years to address a 
variety of questions [41, 205]. For instance, to compare the means of two groups 
of curves, a simple approach is to perform pointwise 𝑡-test (similar to what we 
did for a single point in time in chapter 2) across a sufficiently large grid of time 
points [205]. In the simplest form, a common covariance function (a.k.a. pooled 
sample covariance) can be assumed for all curves. However, if this assumption is 
not valid (as it is typically the case), a separate covariance function is assumed 
for each group in what is commonly referred to as Behrens-Fisher problem for 
functional data [206]. If one prefers a global test with a single summary of the 
evidence about the equality of means, L2-norm-based statistics can be used, in 
which pointwise differences between the mean functions are integrated across 
the entire time frame [207]. Taylor et al. proposed another approach in which the 
maximum of the absolute value of 𝑡-statistics over all 𝑡 was taken as test statistic 
[208]. To further account for the within-group heterogeneity of curves, Berk et al. 
proposed a functional 𝑡-type statistic, in which the L2-norm between the two 
mean curves was further divided by functional standard error [209]. Hotelling’s 
T-squared statistic is yet another approach to test the equality of mean functions 
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from two samples of functional data [210]. Among the existing methods, the 
functional F-test proposed by Shen and Faraway is particularly appealing for 
GSA as it allows for individual smooth curves to be estimated a priori, and takes 
both within- and between-group heterogeneity of curves into account [153]. 
Furthermore, by utilizing a permutation scheme to obtain the null distribution of 
the test statistic, we can properly take the inter-gene correlation among the 
members of a given set into account, and thus successfully meet our three 
criteria. It is worth noting that permutation of group labels inherently extends 
the null hypothesis from equality of means to equality of functional distributions. 
Future work may involve comparing different methods or devising ensemble 
approaches by combining two or more functional procedures. 
 
Accounting for inter-gene correlation is a key advantage of both methods 
implemented in this work. It has been shown that gene-gene correlations among 
members of the set are not negligible for most gene sets, and if overlooked could 
lead to strongly inflated type I error rates [129, 132, 211]. Inter-gene correlation is 
expected in gene sets given that by definition gene sets represent groups of 
biologically associated genes. Nevertheless, many GSA methods either directly 
(by employing gene-permutation procedures) or indirectly (via asymptotically 
parametric tests) assume independence of genes and thereby overestimate the 
significance of gene set statistics. Some of the early works addressing the inter-
gene correlation in GSA was focused on de-correlating gene expression data 
[212]. More recently, Wu and colleagues proposed to directly estimate and adjust 
for the contribution of gene-gene correlation to the variance estimate of gene set 
statistic under the assumption of equal variance for gene-level statistics [132]. 
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Building on this approach, Yaari et al. argued that the assumption of equal 
variance is not valid for most gene sets and instead proposed an estimate of 
variance inflation factor obtained directly from the covariance matrix of the gene 
expression data [130]. Although promising, these methods at best provide an 
approximation of the contribution of gene-gene correlation to the variance 
estimate of the gene set statistic. The resampling approach implemented in our 
work, on the other hand, effectively addresses this problem by preserving the 
inter-gene correlation in the data.  
 
Beside gene-gene correlation, multi-modality and redundancy of gene sets 
impose additional practical challenge in GSA. While in most cases heterogeneity 
of signal is indicative of either biological or technical noise, and therefore not of 
interest, some gene sets may be comprised of both up- and down-regulated 
genes that are biologically meaningful. This is typically found in the context of 
signaling pathways where up-regulation of some components within the 
pathway may lead to down-regulation of other components through regulatory 
feedback mechanisms. Both ssGSEA and functional F-test are designed to detect 
gene sets demonstrating concordant activation. While incorporating 
multimodality in functional GSA for time series data does not seem 
straightforward as there is no consensus on how to compare divergent patterns 
between two or more groups, the ssGSA procedures may be more easily adjusted 
to address this issue. For example, Hanzelmann et al. used the modified Kuiper 
test to favor homogenous gene sets over heterogeneous ones [140]. A future 
direction may involve application of the original Kuiper test where accumulation 
of the members of the set at either extreme ends of the ranked list contributes to 
	  	  
129	  
the overall enrichment score. Nonetheless, multi-modality remains an intractable 
challenge in large part due to lack of directionality annotation for most gene sets. 
In the absence of auxiliary information specifying which gene sets are made up 
of both up- and down-regulated genes, distinguishing trivial noise from 
heterogeneous yet biologically meaningful shift in gene set activity is difficult. 
Another limitation is the redundancy or overlap of gene sets in a database. For 
instance, closer inspection of the top 20 gene sets identified by applying 
functional F-test to the REACTOME database reveals that with the exception of 
three gene sets, all other hits refer to cell cycle or DNA repair and replication. In 
fact, these gene sets also showed similar temporal pattern. While the overlap 
among gene sets may be biologically justified as a result of genes contributing to 
different biological processes or signaling pathways, gene set overlap can be 
problematic for GSA. In fact recent studies have underlined this issue and tried 
to address it by detecting and removing false positives hits that are based on 
overlap with other gene sets [213]. A future direction may involve incorporating 
similar strategies in the functional approaches to GSA. 
 
Complementary to single-sample GSA and functional F-test, coexpression 
network analysis revealed yet another application of gene-centric biological 
knowledge in predicting the functional role and biological contribution of genes 
that are unknown or less studied in the context of wound healing. Importantly, 
in agreement with previous report by Opgen-Rhein and Strimmer [152], we 
showed that use of Pearson correlation led to a sparse coexpression network for 
DicerKO-up macrophage transcriptional signature. Given that members of the 
DicerKO-up gene set are expected to be highly positively correlated, the more 
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densely connected network obtained by dynamic correlation indicates that 
compared to ordinary Pearson correlation, dynamic correlation is able to retain 
additional information about dependency of gene expression trajectories in time 
series microarray data. Overrepresentation analysis of the Paxillin coexpression 
module based on pairwise dynamic correlations revealed several key regulatory 
roles for Paxillin during wound healing. Interestingly, while Paxillin has not 
been studied in the context of cutaneous wound healing, recent studies in cancer 
biology has suggested its involvement in regulating angiogenesis and 
inflammatory response [147,	   214-­‐216]. Although our findings are yet to be 
validated in vivo, these results suggest that Paxillin may hold potential as a 
novel therapeutic or prognostic target in wound care management. Finally, while 
we focused on guilt-by-association prediction, coexpression network analysis can 
also be used to identify candidate genes or to perform differential coexpression 
analysis [134]. Future work will include further investigation of gene 
coexpression networks in db/db wounds compared to db/+. Moreover, 
although dynamic correlation is clearly superior to ordinary Pearson correlation 
in capturing temporal dependencies, additional work is required to more 
thoroughly compare dynamic correlation with alternative similarity metrics for 
time series data.  
 
3.6. Conclusions  
 
In the first part of this chapter, we utilized FDA to extend an existing single-
sample GSA to time course studies. We applied this approach to a large 
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compendium of gene sets representing various signaling pathways and 
biological interactions, and identified several interesting gene sets, many of 
which shown previously to be implicated in impaired diabetic wound healing. 
Building on our previous attempt at analyzing the transcriptional response of 
genes associated with macrophage M1-M2 activation states, we used this 
approach to explore the enrichment of both in vitro- and in vivo-derived 
macrophage transcriptional signatures in db/+ and db/db wounds. In the 
second part, we applied a functional F-test to compare the temporal variation of 
gene sets over the course of healing, while taking the heterogeneity among the 
members of the set into account. Finally, we applied FDA to quantify the 
temporal dependency of gene expression profiles to construct gene coexpression 
networks and infer about the biological role of Paxillin in cutaneous wound 
healing. Taken together, these findings demonstrate the power and flexibility of 
FDA to interpret whole-genome transcriptional response during wound healing 
by extending the single-gene perspective to gene set and network perspectives. 
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